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 Chronic myeloid leukemia (CML) is identified by the unique reciprocal 
chromosomal translocation involving BCR and ABL1, the fusion of which generates a 
constitutively active tyrosine kinase. Of critical importance for kinase function is 
oligomerization of multiple BCR-ABL1 proteins, facilitated by the N-terminal coiled-coil 
(CC) domain in BCR. While antineoplastic therapies have historically been dominated by 
small molecule drugs with a broad impact on cancer, recently there has been a shift 
toward small molecule targeted therapeutics, which was led by the development of 
imatinib. Imatinib, a tyrosine kinase inhibitor (TKI), was rationally developed for the 
treatment of CML. Although imatinib has been extremely successful in disease 
modification and increasing overall survival, it, like many of the subsequently developed 
TKIs, is subject to failure when mutations in the BCR-ABL1 kinase domain (the target of 
TKIs) occur, or the cell loses its dependence on the BCR-ABL1 protein. We have broken 
from the small molecule development track and instead focused on peptide-based 
inhibition of the upstream oligomerization event in CML pathogenesis. 
We previously described the anticancer activity of a dimerization inhibitor 
derived from the CC domain, called CCmut2/3 (representing two different versions of 
coiled-coil inhibitors). Driven by the positive results in previous studies, we proposed the 
following overarching hypothesis: Differential manipulation of domains within one BCR-
ABL1 protein; or parallel manipulation of multiple pathways within one 
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BCR-ABL1-containing cell will lead to a potent therapy which may overcome TKI-
resistant disease. Here we examine this hypothesis to determine the efficacy of the 
CCmut2/3 for broad-spectrum CML disease. 
In one study we observed that use of the CCmut2 in concert with one of several 
selective leukemia-specific secondary pathway inhibitors enhances the apoptotic potential 
and limits the proliferative capacity of K562 BCR-ABL1-containing cells. Another study 
describes the broad anticancer inhibitory potential of CCmut3 in cells with varying 
mutational status in the BCR-ABL1 kinase domain. Finally we investigate the potential 
of CCmut3 in the context of human disease with a series of ex vivo inquires using patient 
samples. This dissertation focuses on demonstrating efficacy of CCmut2/3 as a front-line 
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"Although progress is being made towards the development of a ‘global’ pan-BCR-ABL 
inhibitor that inhibits the full spectrum of identified imatinib-resistant BCR-ABL point 
mutants (including T315I), the potential for the evolution of new drug-resistant point 
mutations in BCR-ABL at crucial points that influence drug binding, protein expression 
or protein activity continues to exist. This prediction justifies the continued development 
of more potent BCR-ABL inhibitors with their own unique mutagenicity profiles, as well 
as the continued use of more than one BCR-ABL inhibitor in combination. It also 
warrants the use of specific signal transduction inhibitors in combination with BCR-ABL 
inhibitors to achieve highly efficacious therapy with a reduced potential for the 
development of drug resistance." 
-Ellen Weisberg, Paul W. Manley, Sandra W. Cowan-Jacob, 
Andreas Hochhaus & James D. Griffin. 
-Nature Reveiws Cancer, 2007 
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 Targeted small molecule therapeutics for treatment of chronic myeloid leukemia 
(CML) are now plentiful, yet still not curative, and are prone to resistance. The first 
orally available targeted tyrosine kinase inhibitor, imatinib (Gleevec®), for cancer 
therapy was developed for CML (1). Reaching that milestone represented a paradigm 
shift in treatment and outcome of this disease. Specifically, imatinib transformed a 37.7% 
5-year survival rate (2) to 89% for patients who received this new drug as initial therapy 
following diagnosis (3). In the last decade since the initial adoption of imatinib 
(Gleevec®) as front-line therapy for CML, four other targeted tyrosine kinase inhibitors 
(TKIs) have been approved for CML treatment by the United States Food and Drug 
Administration (FDA): second (dasatinib (Sprycel®); nilotinib (Tasigna®); bosutinib 
(Bosulif®)) and third (ponatinib (Iclusig®)) generation drugs have all been developed to 
address resistance to previous-generation drugs (4-7). While each new small molecule 
drug is able to address more and different mutant forms of the oncogenic protein, 
resistance to single-agent small molecule therapy continues to be a problem (8, 9). 
 All current targeted therapies for CML address the aberrant and constitutive ABL 
tyrosine kinase activity of the oncogenic fusion protein BCR-ABL1, the causative 
transforming event in CML (10, 11). Surprisingly, little attention has been given to the N-
terminal fusion partner BCR which harbors the coiled-coil dimerization domain. 
Dimerization of BCR-ABL1 is an upstream and necessary event that leads to ABL1 
tyrosine kinase phosphorylation through transactivation (12). In fact, wild-type BCR-
ABL1 proteins lacking the N-terminal dimerization domain do not result in an oncogenic 
phenotype in vitro. We recently designed a mutated coiled-coil (CC) domain derived 
from the wild type dimerization domain of BCR-ABL1 (CCmut) that competitively 
interacts with endogenous BCR-ABL1 to disrupt downstream oncogenic pathways (13, 
14). The design and construction of these constructs for BCR-ABL1 inhibition will be 
discussed in some detail in this introductory chapter. Additionally, some initial testing in 
BCR-ABL1-containing cell lines will be presented. 
 The following chapter will discuss the clinical course of CML including 
historical, current standard-of-care, and new strategies in development for disease 
treatment. A common thread throughout this work will be the topic of disease resistance 
– this includes both BCR-ABL1-dependent resistance and BCR-ABL1-independent 
resistance. Briefly, BCR-ABL1-dependent resistance is the phenomenon that occurs 
when a change within the BCR-ABL1 molecule, typically a mutation within the tyrosine 
kinase domain, confers resistance to a therapeutic (15, 16). BCR-ABL1-independent 
resistance involves a change within the cell that harbors BCR-ABL1, where the cell is no 
longer addicted to/dependent on the oncogenic driver BCR-ABL1 to survive (17, 18). 
The latter poses a problem because these cells are difficult to irradicate with a single 
agent targeted therapy. 
 To address the early potential of coiled-coil combination therapy, selective 
2
secondary agents were tested to determine their ability to enhance killing of BCR-ABL1 
containing cells. Secondary agents were chosen on the ability to circumvent damage to 
normal hematopoietic cells, which becomes important in managing the health of an 
individual with CML (19-22). This work is discussed in detail in Chapter 3. Finally, the 
potential of the CCmut to overcome BCR-ABL1-dependent resistance is also addressed. 
Because the main driver of TKI development has been to develop a drug that is more 
effective against multiple possible BCR-ABL1 mutants, the activity of the CCmut against 





The Breakpoint Cluster Region 
 
 Prior to its discovery as an associated gene partner of the BCR-ABL1 fusion gene, 
little was known about the breakpoint cluster region (BCR) gene or the biologic 
ramifications of its protein activity. BCR is classified by its ability to activate guanosine 
triphosphate (GTP) hydrolyzing enzymes (GTPases), also known as a GTP-ase-activating 
proteins (GAPs) (23). Specifically, BCR is a GAP for the Ras-related GTP-binding 
protein RAC1 (23). Transient RAC1 interaction is dependent on a GTP-bound state 
within a GAP domain (24). The RAC-GAP domain is found in the C-terminus of full 
length BCR (approximately 160 kDa) and is lost in most recombination events with ABL 
(partially retained in p230 BCR-ABL) (25). Moving backward from the C-terminus, BCR 
also contains a site for Rho-guanine nucleotide exchange factor (GEF) binding within the 
DH/PH domain, which in addition to promoting GEF function also facilitates protein-
protein interactions (26-28). The remaining functional properties arise from the CC 
3
domain, which will be discussed more extensively later in this chapter, and the 
serine/threonine (S/T) kinase domain. The S/T kinase domain is responsible for both 
auto- and transphosphorylation activity (29). Most importantly, phosphorylation of Y-177 
enables the binding of growth factor receptor 2 (GRB2) and other scaffolding proteins 
which initiate several signaling cascades important in cell survival, proliferation and 
transcription (30). It is through autophosphorylation of this domain that the activity of 
BCR, in the context of a BCR-ABL1 fusion protein, is switched (31, 32). 
 While the interactions and function of BCR described above are known, the 
predominant function of BCR in the context of human health and disease (beyond CML) 
is not well understood. A myriad of reports suggest varying roles for BCR in gross cell 
events and specific physiological activities. Kinase activity of BCR is hypothesized to be 
responsible for trafficking of growth factor receptors (GFR) including epidermal GFR 
(EGFR), as well as mediating transcriptional activity by interactions with peroxisome-
proliferator-activated receptor gamma (33, 34). Functions of BCR and a homologous 
protein, active BCR related (ABR), are now being described together in some studies 
(35). BCR and ABR appear to be important in inflammatory responses, memory- and 
learning-related synaptic plasticity, and are potentially important in bipolar disorder (36-
38). While some of these functional properties described are mediated by known domains 
(e.g., synaptic plasticity regulation by the RAC-GAP domain), the larger picture of how 







Abelson Tyrosine-Protein Kinase 1 
 
 The cellular Abelson Protein Tyrosine Kinase 1 (c-Abl) is encoded by the ABL1 
gene and produces a 140 kDa protein classified as a nonreceptor tyrosine kinase (39). 
Perhaps most interesting is the reciprocal role of a tightly regulated proapoptotic protein 
tyrosine kinase 1 vs. the constitutively active antiapoptotic and oncogenic BCR-ABL1 
within the cell (40). Of the two c-Abl isoforms (1a and 1b) both contain an N-terminal 
“cap” region that in the Abl 1b isoforms is myristoylated (41). Myristoylation along with 
autoinhibition, molecular interactions, a multitude of protein interactions, and specific 
subcellular localization contribute to the spatiotemporal regulation of proapoptotic 
function of c-Abl (39, 42-44). DNA damage is a key trigger responsible for activation of 
c-Abl. Upon DNA damage, the PI3K-related protein kinases ATM and ATR depend on 
c-Abl-mediated control of cell cycle progression, apoptosis, and DNA repair. Signaling 
through c-Abl feedback dictates activation of ATM and ATR substrates, Chk2 and Chk1, 
respectively (45). Additionally, c-Abl relays signaling from ATM and ATR to pro-
apoptotic p73, p63, p53 and Yap (46, 47). In addition to the initiation and propagation of 
the DNA-damage response, c-Abl plays a direct role in regulating cleavage of caspases in 
both effector (3, 7) and initiator (8, 9) classes (48-51). 
 
 
Chronic Myeloid Leukemia 
 
BCR-ABL1 
 The acquired BCR-ABL1 rearrangement is formed through a reciprocal 
translocation between BCR (breakpoint cluster region) and ABL1 (c-abl oncogene 1) 
t(9;22) [q34.1;q11.21] in the hematopoietic stem cell (HSC) (10, 11, 52, 53). This 
5
recombination results in a lengthened chromosome 9 (containing ABL1-BCR) and a 
shortened chromosome 22 (with the coding region for BCR-ABL1), also known as the 
Philadelphia (Ph) chromosome (Figure 1.1) (54, 55). This single event is responsible for 
transforming a normal HSC into a leukemia stem cell (LSC), and the expression of BCR-
ABL1, but not ABL1-BCR, within the LSC is able to confer a proliferative advantage to 
the LSC and its daughter cells over normal hematopoietic cells (10, 52, 56).  
 While this work will focus on BCR-ABL1 primarily in the context of CML (the 
Ph chromosome is present in the vast majority of cases, but the BCR-ABL1 translocation 
is missing in patients with chronic myelomonocytic leukemia or Ph-negative CML), it is 
also important to note that the Ph chromosome also appears in approximately 25% of 
acute lymphoblastic leukemia (ALL) cases (57-59). The breakpoint between BCR and 
ABL1 primarily forms a 210 kDa protein in CML while a 190 kDa protein is seen in the 
majority of ALL cases (60). Although the mechanism behind the differential generation 
of BCR-ABL1 breakpoints is unknown, recent work does suggest there are different 
mechanisms which generate the p190 lymphoid (ALL) vs. p210 myeloid (CML) 
breakpoints (60). While further discussion of the breakpoint mechanism is beyond the 
scope of this work, it is important to note that both p190 and p210 BCR-ABL1 contain 
the BCR N-terminal dimerization domain and the ABL1 tyrosine kinase domain. 
 The BCR-ABL1 fusion oncogene is transcribed and translated into the 
constitutively active fusion protein tyrosine kinase BCR-ABL1 protein containing the 
following domains depicted in Figure 1.2. First, the main topic of the following chapters, 
the coiled-coil dimerization domain (CC), occupies the N-terminus of BCR. Next, a 
protein serine/threonine kinase domain (S/T kinase) is followed by the Dbl 
6
 Figure 1.1 The chromosomal rearrangement of BCR-ABL1. ABL1 resides on the 
long arm of normal chromosome 9, while BCR is located on the long arm of chromosome 
22. Following a reciprocal translocation, changed chromosome 9 (Δ9) is lengthened and 
now contains an ABL1-BCR fusion product. Changed chromosome 22 (Δ22) is 
shortened, called the Philadelphia chromosome, and harbors the oncogene BCR-ABL1. 
7



































































































































































































































































































homology/Pleckstrin homology domain (DH/PH). Following the breakpoint in BCR, the 
domains in ABL1 include the Src-homology domains 3/2 (SH3/SH2) and current focus of 
drug therapy, the protein tyrosine kinase domain (Y-kinase). Finally the C-terminus of 
ABL1 includes both a DNA-binding and actin-binding domain (DBD/ABD) (61, 62). 
 While normal function of c-Abl (the protein expressed from a normal 
chromosome 9) is regulated by an N-terminal “cap” of approximately 80 residues (63-
65), fusion to BCR results not only in the truncation of this regulatory region, but also 
enables oligomerization of BCR-ABL1 by the CC domain (66, 67). This antiparallel 
dimerization of BCR-ABL1 will then stack with a second dimer pair to form a tetramer 
(12). This arrangement is responsible for the transphosphorylation of tyrosine residues in 
ABL1 (68). Additionally, the cellular localization of c-Abl changes from a primarily 
nuclear to exclusively cytoplasmic spatial localization upon BCR-ABL1 fusion (69). The 
culmination of a change in subcellular location and constitutive phosphorylation results 
in a greatly increased diversity of interaction partners which can associate with the 
tyrosine kinase domain. (69, 70). 
 
 
Downstream Targets of BCR-ABL1 
 
 The constitutively activated BCR-ABL1 tyrosine kinase initiates signaling 
cascades from both BCR and ABL1. Though most of the focus thus far has indicated c-
Abl aberrant kinase activity is the key oncogenic driver, BCR is not simply a bystander in 
the genesis of the CML disease state. BCR has several key residues for phosphorylation 
in the S/T kinase domain, the best studied of which is Y-177. Phosphorylation of c-Abl 
on Y-245 and Y-412 are required for kinase activity (63). Phosphorylation of c-Abl Y-
9
245, located between the SH2 and kinase domain of c-Abl, is responsible for the 
autophosphorylation event to activate BCR-mediated signaling in BCR-ABL1 (71). Upon 
phosphorylation of BCR Y-177, a high-affinity site for GRB2 is generated. GRB2 
initiates scaffolding for GRB2-associated binding protein 2 (GAB2), and son of sevenless 
(SOS) binding (43). The consequence of this initiation event is strong activation of pro-
survival and proliferation pathways. These pathways are activated through nodal proteins 
with a documented history of aberrant activity in cancer. These include 
phosphatidylinositol-3 kinase (PI3K), the protein kinase B (AKT) pathway (72), RAS 
(73, 74), and signal transducers and activators of transcription (STAT) proteins (75, 76), 
specifically STAT3/5, and Janus kinases (JAK1/2) (77, 78). The BCR-ABL1 fusion 
oncoprotein is responsible for constitutive kinase activity able to induce malignant 
transformation by disrupting cell proliferation and differentiation (74, 79-81), cell 
survival (82-85) and cell adhesion and migration (Figure 1.3) (86-88). 
 
 
Disease Statistics, Treatment and Resistance 
 
 A complete discussion of clinical disease presentation, progression, as well as 
historic and future therapeutic development avenues can be found in Chapter 2. However, 
a brief overview will be presented here for clarity of the following sections in this 
chapter. 
 CML is characterized by three disease phases: chronic, accelerated, and blast 
crisis (89). More than 90% of patients are now diagnosed in an indolent chronic phase 
and generally present with constitutional symptoms, enlarged spleen, and leukocytosis. 

























































































































































































































































































then rapidly to an acute blast crisis phase, a hallmark of which is expansion of 
undifferentiated cells in the bone marrow and into the peripheral blood (89, 90). CML is 
fatal if not treated. While the exact molecular events leading to blast crisis phase disease 
are unknown, the proposed mechanism behind CML-progression is a process known as 
clonal evolution, represented by new chromosomal abnormalities, including gene 
amplification, mutations, and rearrangements (91, 92). 
 CML accounts for approximately 12% of all leukemias, and there are about 5,000 
new cases of CML each year in the United States. The median age of diagnosis is 65 
years old, while CML-related mortality also rises with age, peaking between 75 and 84 
years of age (Figure 1.4A). Currently the only available curative therapy for CML is 
allogenic stem-cell transplantation. However, complications involving donor 
compatibility and treatment tolerance limit the feasibility of this therapy (93, 94). The 
alternative and first-line therapy for patients with CML is the drug class known as TKIs. 
Imatinib (IM) and other ABL1-targeted TKIs antagonize the causative oncogenic and 
constitutively active nonreceptor tyrosine kinase BCR-ABL1. Treatment with the decade-
long TKI therapeutic veteran, imatinib, is initially effective in the majority of patients 
(48-51); however acquired resistance to this drug class may develop leading to disease 
progression (95). Second generation TKIs can effectively treat some IM-resistant strains 
of CML (4, 5, 96-99), but are ineffective against certain mutants (100). The most recent 
pan-BCR-ABL1 inhibitor, ponatinib, exhibits the most promising array of activity against 
all known BCR-ABL1 mutants. Ponatinib was developed specifically to address the 
elusive T315I, or “gatekeeper,” mutation in BCR-ABL (101). Although these single-
agent small molecule inhibitors now have a strong foothold, experts theorize that 
12
 Figure 1.4 Incidence, mortality and resistance in CML. (A) Incidence and mortality of 
CML. CML incidence increases with age, with the median age at diagnosis of 65 years 
old. Disease-related mortality also increases with age with the highest percent occurring 
between 75-84 years. This data was compiled using the National Institutes of Health 
Surveillance Epidemiology and End Results (SEER) data from 1975-2009. (B) Increasing 
focus on CML resistance. Frequency of the keyword terms “CML” and “resistance” 
found in the U.S. National Library of Medicine, National Institutes of Health PubMed 























































































resistance to this drug class is inevitable (9). However, work continues to explore the 
mechanism behind “mutational escape,” and has led to a flurry of publications attempting 
to identify mechanisms of TKI resistance in CML (Figure 1.4B). 
 Disease persistence is a separate, but equally important subject pertaining to the 
population of Ph-positive LSCs, which, despite complete inhibition of BCR-ABL1, cells 
do not die. While TKIs can effectively kill peripheral Ph-positive cells, quiescent cells 
which reside in the bone marrow microenvironment cannot be completely eliminated (18, 
70). This persistent population of cells is the probable origin of CML recurrence in the 
majority of patients who discontinue therapy (102, 103). It is important to note that TKIs 
are not curative, and ultimately their continued use increases CML prevalence. 
 To summarize, TKI-resistance and disease persistence can be broken down more 
simplistically into: 1) BCR-ABL1-dependent resistance; and 2) BCR-ABL1-independent 
resistance. Long-term single-agent disease management has been the preferred treatment 
strategy since the adoption of imatinib as the standard-of-care therapy. The second-
generation TKIs dasatinib and nilotinib have first sought approval for imatinib-resistant 
indications before gaining accelerated approval for first-line indications. In all cases, 
drugs are administered over a consistent dose and constant schedule until there is 
indication of failure (104, 105). If a reason can be determined for the failure (e.g., 
detection of a kinase mutation in BCR-ABL1 by genotyping) the patient is transitioned to 
a more advanced TKI able to circumvent the problem or to a clinical trial where no 
therapies are available (106). Although theoretically BCR-ABL1-dependent resistance is 
solvable (107), the progression of disease will eventually outpace the lag between 
discovery and development, and there will be no advanced TKI to which to turn (108, 
14
109). 
 In addition to BCR-ABL1, many key regulatory proteins have been implicated in 
CML persistence. Multiple-agent therapies are currently in clinical trials, beginning with 
TKI combinations, and are aimed at addressing the residual population of Ph-positive 
LSCs residing in the bone marrow (9). Some of these secondary agents broadly target all 
HSCs, similar to older broad-spectrum antineoplastic drugs. These key regulatory 
proteins, such as FOXO, PML, Hh/Smo (Hedgehog), and Wnt/β-catenin, may not be 
optimal targets since they regulate other critical HSC cellular functions in addition to 
promoting CML (110-113). Indeed, other combinations are “smarter” and attempt to 
knock out pathways specifically affected by the transition to BCR-ABL1 independence 
(114-118). Targeting key proteins that are either unique to or overexpressed in CML cells 
can be a better option, as a restricted expression profile provides an opportunity to 
explore the potential of RNAi therapies or specific small molecule inhibitors targeting 
these proteins or pathways. Several reports demonstrate enhanced potency using RNAi 
targeting drug efflux pumps, the autophagy pathway, or the Wnt/Ca2+/NFAT signaling 
axis in combination with current TKIs (114, 119, 120). The synthetic lethality concept, as 
well as the multiple target/dual hit hypothesis are described in more detail in Chapter 2. 
Because the solution to eliminate all BCR-ABL-independent LSCs is still elusive, a 
viable secondary target must be identified and combined with a potent BCR-ABL1 












 The therapeutic potential of targeting the coiled-coil domain in BCR-ABL1 has 
yet to be fully explored in CML. Previous efforts to explore the importance of the CC 
domain in CML have centered on downstream events such as BCR or ABL1 
phosphorylation (121-123). However, as previously discussed, the oligomerization of 
BCR-ABL1 is necessary for ABL1 transactivation, and absence of this domain in vitro 
causes loss of oncogenicity (12). Ruthardt et al. did explore the therapeutic potential of 
virally introducing a portion of the CC defined as the α2 helix (Figure 1.5) into a p185 
BCR-ABL1 expressing cell line as a competitive inhibitor. They reported that this 
therapeutic: 1) interfered with the transformation potential of BCR-ABL1 and increased 
sensitivity to imatinib; and 2) potentially forced a BCR-ABL1 monomeric state and could 
effectively inhibit some imatinib-resistant BCR-ABL1 mutants with the exception of the 
T315I mutant (124, 125). Our laboratory has recently attempted to improve the 
therapeutic potential of the wild-type CC in hopes of producing a more potent and 
universal BCR-ABL1 inhibitor. 
The CC consists of 72 amino acids and structurally folds into two distinct α-
helixes joined by a short linker. The α1 helix is shorter and on the N-terminus is 
comprised of amino acids (AA) 5-15, while the α2 helix is longer (AA 28-67) and 
contains the antiparallel homodimerization interface (Figure 1.5). While the α2 helix is 
primarily responsible for dimerization through a hydrophobic core of interactions, the α1 
helix can interact with its dimer partner to provide stabilization of the dimer pair through 







Figure 1.5 The coiled-coil domain. Comprised of 72 AA, the CC domain is structurally 
separated into two separate α-helixes. The α1 helix is close to the N-terminal portion 
while the α2 helix makes up the majority of the domain and is also primarily responsible 
for dimer interactions. This ribbon diagram of the CC was generated by James Robertson 









 We recently designed a mutated coiled-coil (CCmut2) derived from the wild-type 
dimerization domain of BCR-ABL1 which can bind endogenous BCR-ABL1 to disrupt 
oncogenic function (14). By introducing a competitive mutant CC to the endogenous full-
length BCR-ABL1, we successfully limited the function of the BCR-ABL1 oncoprotein 
and transautophosphorylation of ABL1 tyrosine kinase. To improve oligomerization with 
BCR-ABL1 we mutated five residues to both increase the binding affinity for BCR-
ABL1 (heterodimerization) and reduce binding to other CCmut2 molecules in the cell 
(homodimerization). The binding of the CCmut2 to wild-type Bcr-Abl itself is able to 
reduce proliferation, reduce phosphorylation of BCR-ABL1 and other downstream 
targets, and increase apoptosis. 
 The CCmut2 was first envisioned as a capture motif to bind BCR-ABL1 and, with 
the addition of some clever genetic engineering developed in our group called the protein 
switch (127), move the oncogenic protein from the cytoplasm to the nucleus (128). This 
was an important objective because artificial nuclear localization of BCR-ABL1 can be a 
potent driver of apoptosis (129, 130). However, we discovered that this technology could 
not overcome the tethering, primarily by the actin cytoskeleton, which held BCR-ABL1 
in the cytoplasm (131). 
 Careful analysis of the helical wheel showing the α2 helix dimerization interface 
by Dixon (14) led to proposed mutations to strengthen this interaction. These were 
confirmed and amended following extensive computational modeling by Cheatham and 
Pendley (Figure 1.6) (14). The mutations which proved to be optimal based on modeling 
18
Figure 1.6 Mutant coiled-coil ribbon diagrams. Ribbon diagrams (with corresponding 
helical wheel diagram below) of wild-type homodimer (A), wild-type-CCmut2 
heterodimer (B), andCCmut2-CCmut2 homodimer (C). Gray ribbons (ribbon diagrams) 
or dots (helical wheel diagrams) represent the wild-type coiled coil domain, and cyan 
represents CCmut2. The side chains of key residues (Glu-34, Lys-39, Ser/Arg-41, 
Leu/Asp-45, Glu-46, Glu/Arg-48, Arg-53, Arg-55, and Gln/Glu-60) are shown as red 
(acidic), blue (basic), green (hydrophobic), yellow (serine), or black (glutamine) spheres 
(ribbon diagrams) or font (helical wheel diagrams). Dotted lines indicate possible ionic 
interactions, and solid lines indicate charge-charge repulsions. Ribbon diagrams were 
generated with UCSF Chimera starting with the Bcr coiled coil domain crystal structure 
(Protein Data Bank code 1K1F). 
 
This research was originally published in The Journal of Biological Chemistry. Andrew 
S. Dixon, Scott S. Pendley, Benjamin J. Bruno, David W. Woessner, Adrian A. Shimpi, 
Thomas E. Cheatham III, and Carol S. Lim. Disruption of Bcr-Abl coiled coil 
oligomerization by design. . J Biol Chem. 2011. 286(31):27751-60. © the American 
Society for Biochemistry and Molecular Biology. 
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were C38A, S41R, L45D, E48R, and Q60E. While S41R, E48R and Q60E all increased 
electrostatic interactions, L45D stabilized the heterodimer pair, and C38A, in 
combination with the previously listed mutations, stabilized the heterodimer interaction 
over either homodimer pair (i.e., CC:CC or CCmut2:CCmut2). 
 Importantly, the introduction of CCmut2 in K562 cells significantly reduced the 
phosphorylation of the primary oncoprotein BCR-ABL1. This is especially interesting, 
because Beissert et al. reported significant activity with the wild-type α2 helix-CC, where 
we see little change between the full length CC and a GFP-control (124). However, this 
discrepancy could be a result of differing delivery methods (transfection vs. viral delivery 
by Ruthardt). In addition to the change in p-BCR-ABL, two downstream partners, CrkL 
and STAT5, also show a reduction in phosphorylation (Figure 1.7). Additionally, reduced 
cell proliferation, transformative potential, and increased apoptosis (as measured by 
caspase 3/7) were observed following administration of CCmut2-expressing plasmids to 
K562 cells when compared to controls (Figure 1.8). These hallmarks of apoptosis and 
reduced proliferation were encouraging. Moreover, the proposed disfavoring of 
homodimer and promoting heterodimer formation were strongly supported. For a 






 Although we were encouraged by the efficacy of CCmut2, we hypothesized 
additional improvements to the modified CC could be made, and this work was described 
in Molecular Pharmaceutics (13). A CCmut3 was created which consisted of the same five 
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Figure 1.7 Phosphorylation mitigation by CCmut2. Representative images of Western 
blots to detect phosphorylated form of Bcr-Abl (A) and two substrates of Bcr-Abl, 
STAT5 and CrkL (B) are displayed here. The phosphorylation of Bcr-Abl is indicative of 
the tyrosine kinase activity and is shown to be decreased by the addition of CCmut2 
(percentage of p-Bcr-Abl from untreated K562 cells is indicated graphically). The 
proteins STAT5 and CrkL are also phosphorylated when Bcr-Abl is active and are 
secondary indicators of the Bcr-Abl activity. Western blotting followed by densitometry 
was replicated three times on lysates from three separate transfections. The level of p-
Bcr-Abl, as a percentage of the untreated cells, is shown graphically in A, and the level of 
p-STAT5 and p-CrkL (±S.D.) is indicated above the representative images. Statistical 
significance was determined using one-way ANOVA with Tukey’s posttest (n=3). 
*,p<0.05; **,p<0.01 compared with cells transfected with EGFP. Error bars represent 
±S.D. 
 
This research was originally published in The Journal of Biological Chemistry. Andrew 
S. Dixon, Scott S. Pendley, Benjamin J. Bruno, David W. Woessner, Adrian A. Shimpi, 
Thomas E. Cheatham III, and Carol S. Lim. Disruption of Bcr-Abl coiled coil 
oligomerization by design. . J Biol Chem. 2011. 286(31):27751-60. © the American 
Society for Biochemistry and Molecular Biology. 
21
  
Figure 1.8 Decreased proliferation and apoptosis activation by CCmut2. Inhibition of 
Bcr-Abl through expression of CCmut2 results in decreased proliferation of K562 cells 
and activation of apoptosis. (A) Proliferation of K562 cells as determined by cell counts 
with trypan blue exclusion. (B) Proliferation of K562 cells as determined by colony 
forming assays. (C) Induction of apoptosis as measured through activation of caspase-
3/7. For A–C, statistical significance was determined using one-way ANOVA 
withTukey’s posttest. *, p<0.01; **, p<0.001 compared with control (cells transfected 
with pEGFP-C1). Error bars represent ± S.D. IM, imatinib mesylate. 
 
This research was originally published in The Journal of Biological Chemistry. Andrew 
S. Dixon, Scott S. Pendley, Benjamin J. Bruno, David W. Woessner, Adrian A. Shimpi, 
Thomas E. Cheatham III, and Carol S. Lim. Disruption of Bcr-Abl coiled coil 
oligomerization by design. . J Biol Chem. 2011. 286(31):27751-60. © the American 
Society for Biochemistry and Molecular Biology. 
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mutations described in the previous section (CCmut2) with the addition of K39E in the CC. 
K39E is able to play two roles: first, K39 from the wild-type CC can form a salt bridge 
with E60 in CCmut3 promoting heteroligomerization; second, E39 in CCmut3 forms a 
charge-charge repulsion with E60 in CCmut3 further disfavoring homoligomerization 
(Figure 1.9). Although CCmut3 improved oligomerization properties in silico and in 
binding interaction assays, statistically significant biologic improvements in CML studies 
did not bear out these improvements. Nevertheless, we proceeded using CCmut3 in future 




Statement of Objectives 
 
 The goal of the work discussed in the following studies is to advance feasibility 
studies for the CCmut therapeutic. Although a timeline for delivery to patients is 
premature, preclinical efficacy is an essential hurdle to clear on the path to clinical 
development. This body of work was framed in the context of several hypotheses and 
corresponding aims, as follows: 
1) Hypothesis 1: Inhibition of LSC-specific secondary pathways MUC1, Atg7, and 
Alox5 will induce apoptosis alone or in combination with the CC or CCmut. 
a. Aim 1: Construction and validation of RNAi; combination treatment with RNAi.  
i. Aim 1a: Short hairpin RNAs (shRNAs) against MUC1, Atg7 and Alox5 
transcripts will be constructed and validated using Western blotting.  
ii. Aim 1b: A synergistic or additive effect of RNAi with CC or CCmut on 
apoptosis and proliferation will be assessed by transfecting both agents 
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 Figure 1.9 Ribbon diagrams of the coiled-coil domains. Gray ribbons indicate wild-
type (WT) coiled-coil, white ribbons indicate mutant coiled-coils, and each homodimer 
(A, B, D, and F) or heterodimer (C, E, and G) is labeled above. Blue numbering/spheres 
indicates positively charged amino acid residue; red numbering/spheres indicates 
negatively charged amino acid residue. For the WT, white = C38, blue (+ chg) = K39, 
purple = S41, cyan (hϕ) = L45, red (− chg) = E48, green = Q60. For CC mutants, gray = 
C38A, red (− chg) = K39E, blue (+ chg) = S41R, red (− chg) = L45D, blue (+ chg) = 
E48R, red (− chg) = Q60E. (A) WT:WT homodimer. Only the top strand is numbered. 
(B) CCmut2:CCmut2 homodimer (CCmut2 contains C38A, S41R, L45D, E48R, Q60E 
mutations). The two R41:R48, and one D45:D45 charge-charge repulsion are shown, as 
well as the two sets of K39:E60 salt bridges. (C) WT:CCmut2 heterodimer. The E48:R41 
and K39:E60 salt bridges are indicated. (D) CCmut3:CCmut3 homodimer (CCmut3 
contains C38A, K39E, S41R, L45D, E48R, Q60E mutations). The two sets of K39:E60 
salt bridges are now replaced with two sets of E39:E60 charge-charge repulsions. The 
two R41:R48 and one D45:D45 charge-charge repulsions are retained. (E) WT:CCmut3 
heterodimers. CCmut3 may form E48:R41 and K39:E60 salt bridges with WT as 
illustrated. 
 
Adapted with permission from Molecular Pharmaceutics. Andrew S. Dixon, Geoffrey D. 
Miller, Benjamin J. Bruno, Jonathan E. Constance, David W. Woessner, Trevor P. Fidler, 
James C. Robertson, Thomas E. Cheatham 3rd, and Carol S. Lim. Improved coiled-coil 
design enhances interaction with Bcr-Abl and induces apoptosis. Mol Pharm. 2012. 
9(1):187-95. Erratum in: Mol Pharm. 2012. 9(5):1535. © 2012 American Chemical 
Society. 
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into a BCR-ABL1-positive cell line (K562). 
b. Aim 2: Drugs inhibiting the same target or pathway as RNAi will be combined 
with CC or CCmut to further investigate potential enhancements of apoptosis or 
proliferation. 
2) Hypothesis 2: The efficacy of the CCmut will not be affected by mutations in the 
tyrosine kinase domain that inactivate current TKIs. 
a. Aim 1: A cell line derived from a mouse pro-B cell engineered to express p210-
BCR-ABL1 (Ba/F3-p210) will be transfected with CCmut to demonstrate 
efficacy equal to that of this construct in K562 cells. Parental Ba/F3 cells will be 
used to show lack of toxicity (as a control).  
b. Aim 2: Kinase mutant BCR-ABL1 Ba/F3 cells will be tested to determine 
efficacy of the CCmut by measuring proliferation, cell death, and transformation 
potential. 
3) Hypothesis 3: The mutant coiled-coil therapeutic delivered by lentivirus as a gene-
based therapy to primary CML patient samples in vitro will result in decreased 
proliferation and transformation potential. 
a. Aim 1: Peripheral blood samples from newly diagnosed chronic phase CML will 
be enriched for CD34+ cells and transduced with either CCmut or a control empty 
vector.  
b. Aim 2: Primary cells with or without BCR-ABL kinase mutations will be 
assessed for sensitivity to the CCmut therapeutic. 
 These hypotheses and aims are discussed in the chapters that follow. Chapter 2 
reviews the general disease course for CML as well as historical and current therapies. 
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Discussion of agents under development for CML and perspectives on curative strategies 
are highlighted as published in The Cancer Journal. Chapter 3 tackles Hypothesis 1 as 
published in Molecular Pharmaceutics. Chapter 4 addresses Hypotheses 2 and 3 and is in 
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Development of an Effective Therapy for
Chronic Myelogenous Leukemia
David W. Woessner, BA,* Carol S. Lim, PhD,Þ and Michael W. Deininger, MD, PhDþ
Abstract: Targeted small-molecule drugs have revolutionized treat-
ment of chronic myeloid leukemia (CML) during the last decade. These
agents interrupt a constitutively active BCR-ABL, the causative agent for
CML, by interfering with adenosine 5¶ triphosphateYdependent ABL
tyrosine kinase. Although the efﬁcacy of tyrosine kinase inhibitors
(TKIs) has resulted in overall survival of greater than 90%, TKIs are not
curative. Moreover, no currently approved TKIs are effective against the
T315I BCR-ABL variant. However, a new generation of TKIs with ac-
tivity against T315I is on the horizon.Wewill highlight the clinical utility
of historical CML therapeutics, those used today (ﬁrst- and second-
generation TKIs), and discuss treatment modalities that are under de-
velopment. Recent advances have illuminated the complexity of CML,
especially within the marrowmicroenvironment.We contend that the key
to curing CML will involve strategies beyond targeting BCR-ABL be-
cause primitive human CML stem cells are not dependent on BCR-ABL.
Ultimately, drug combinations or exploiting synthetic lethality may
transform responses into deﬁnitive cures for CML.
Key Words: Chronic myeloid leukemia, BCR-ABL, tyrosine kinase
inhibitors, drug resistance, synthetic lethality
(Cancer J 2011;17: 477Y486)
Chronic myeloid leukemia (CML) is one of the most exten-sively studied cancers, and a highly treatable disease with
overall survival greater than 90% using current therapies.1Y3
Chronic myelogenous leukemia results from a reciprocal transl
ocation between chromosomes 9 and 22 [t(9;22)(q34;q11)], which
is thought to occur in a hematopoietic stem cell. The derivative
chromosome 22, originally believed to be a shortened 22, is
commonly referred to as Philadelphia chromosome (Ph). As a
result of the translocation, fusions are formed between the
breakpoint cluster region (BCR) gene on chromosome 22 and the
Abelson oncogene (ABL) on chromosome 9. BCR-ABL, which
resides on Ph, is critical to disease pathogenesis, whereas its re-
ciprocal ABL-BCR does not seem to play any major role.4,5 The
BCR-ABL protein, a constitutively active tyrosine kinase, drives
survival and growth of CML cells.6 This tyrosine kinase activity
was subsequently exploited for targeted CML therapy with the
development of the ﬁrst successful tyrosine kinase inhibitor (TKI)
imatinib.7 Although CML accounts for only 20% of all adult and
2.6% of childhood leukemias in the United States,8 it has become
a paradigm of successful cancer therapy based on a rational
treatment approach.
Patients are typically diagnosed in the chronic phase of
CML (CP-CML) and usually present with constitutional symp-
toms, splenomegaly, and left-shifted neutrophilic leukocytosis.
However, at least in developed countries, the disease is frequently
discovered when an abnormal ‘‘routine’’ blood count leads to a
diagnostic workup. The chronic phase is characterized by an ex-
pansion of the myeloid cell compartment, with preserved ter-
minal differentiation. In the absence of efﬁcient therapy, there is
inexorable progression to accelerated phase (AP) and blastic
phase/blast crisis (BP or BC), which are characterized by a
gradual or sudden loss of differentiation capacity, poor response
to treatment, and short survival.9
During the ﬁrst half of the 20th century, treatment was
largely limited to splenic irradiation, which offered pain control
but no survival beneﬁt. Effective drug therapy for CML began in
1953 with oral busulfan, an alkylating agent. Busulfan’s use was
limited by signiﬁcant myelosuppression, marrow ﬁbrosis, and
prolonged aplasia but remained the preferred therapy for almost
20 years and is still in use as part of conditioning regimens in
allogeneic stem cell transplantation.10 Hydroxyurea, an inhibitor
of ribonucleotide reductase, was introduced into CML therapy
in 1972 and improved median survival rates over busulfan from
44 to 58 months; however, neither therapy prevented progression
to BC-CML.11Y13 Allogeneic hematopoietic stem cell transplant
(allo-SCT), pioneered by the Seattle group in the mid-1970s, was
the ﬁrst therapy known to induce a state of Ph-negativity and is
still considered the only therapy with the potential of curing
CML. Incremental improvements to transplant technology, such
as better supportive care and high-resolution HLA typing, led to
greatly improved outcomes.14 Today, treatment algorithms re-
serve allografting for patients with progression to AP/BC.15Y17
Interferon > (IFN->) entered the therapeutic space in the
mid-1980s and was the ﬁrst drug that induced a cytogenetic
response.18 The exact mechanism for the antileukemic effect is
not known but may involve enhanced immune surveillance, mod-
ulation of hematopoiesis, and/or interleukin signaling, resulting in
selective toxicity to the leukemic clone.19,20 In randomized con-
trolled trials, the 6-year survival for patients on IFN therapy was
50%, much superior to chemotherapeutics (29% at 6 years with
either busulfan or hydroxyurea).21,22 Subsequent studies ex-
plored the combination of IFN with cytarabine, which had pre-
viously shown some activity as a single-agent for CML. On the
basis of a randomized comparison, this combination advanced
to standard-of-care drug therapy in the mid-1990s.23 Still, only
a minority of patients achieved durable responses, and most pa-
tients eventually progressed to BC. Therefore, the treatment al-
gorithm was to offer an allogeneic stem cell transplant to all
eligible patients, leaving the majorityVthose without a suitable
donor or with prohibitive comorbiditiesVwith IFN as their best
option.24,25
With the advent of imatinib and the second-generation
TKIs dasatinib and nilotinib, small-molecule drugs have become
the mainstay for ﬁrst-line CML management.26Y29 The success
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of TKI therapy has drastically improved patient survival, and
projections indicate that CML prevalence will continue to in-
crease as a result. In fact, it has been estimated that there may be
up to 250,000 CML patients in the United States in 2040.30
Tyrosine kinase inhibitors are very effective inhibitors of
BCR-ABL kinase activity; second-generation agents are more
potent, and they have expanded inhibition against various BCR-
ABL mutants resistant to the ﬁrst-generation drug, imatinib.31
As we mark a decade of imatinib use, we have developed an
understanding of disease response to these targeted agents, al-
though many questions still remain. Will long-term BCR-ABL
inhibition by TKIs eradicate all disease-causing cells, at least
in some patients? If not, how can this be accomplished? Will
it be possible for one compound to completely inhibit all BCR-
ABL variants, including the T315I gatekeeper mutant? This
review will discuss currently approved standard-of-care drugs
and highlight promising novel agents. In addition, we will cover
therapeutic roadblocks, such as targeting the bone marrow mi-






Disease stage is monitored using peripheral blood and
marrow differentials, marrow cytogenetics, BCR-ABL detection
by ﬂuorescence in situ hybridization (FISH), and BCR-ABL
copy number surveillance by quantitative real-time polymerase
chain reaction (PCR). Normalization of blood counts and spleen
size is termed complete hematologic remission (CHR) and is the
earliest measure of response. Cytogenetic response is measured
as the percentage of Ph+ karyotypes in 20 bone marrow meta-
phases. Zero Ph metaphases constitutes a complete cytogenetic
response (CCyR); 1% to 35%, a partial response (PCyR); 30% to
65%, a minor response; and 66% to 95%, a minimal response.32
Major cytogenetic response (MCyR) includes both CCyR and
PCyR. A major molecular response is deﬁned as a 3-log re-
duction of BCR-ABL messenger RNA compared with a stan-
dardized baseline as measured by quantitative real-time PCR.33
For an excellent perspective on response to TKI therapy, please
see the recent review by Radich.34
Imatinib
Imatinib mesylate (STI571/Gleevec; Novartis) is a com-
petitive inhibitor of the adenosine 5¶ triphosphate (ATP)Ybinding
site of the BCR-ABL tyrosine kinase. Its development is regarded
as a prototype for structure-based design of speciﬁcally targeted
inhibitors.35 Preclinical efﬁcacy was described ﬁrst in patient-
derived BCR-ABLYexpressing cells and ﬁnally in a mouse model
expressing BCR-ABLYpositive cells.36 A phase I trial included
an initial cohort of 83 patients. Despite dose escalation up to
1000 mg daily, the maximum tolerated dose was not achieved,
and 400 mg/d was selected as an effective dose.7 Clinical efﬁ-
cacy (phase II) studies were conducted for each disease phase (CP,
AP, and BC) enrolling more than 1000 patients. Impressively,
these studies conﬁrmed or surpassed the efﬁcacy seen in phase
I but also conﬁrmed that responses in AP/BC are less frequent
and less durable.37Y39 The phase III International Randomized
Study of Interferon and STI571 (IRIS) study demonstrated clear
superiority of imatinib over IFN plus low-dose cytarabine for
CP-CML. Speciﬁcally, at 18 months, freedom from progression
to AP/BC was 96.7% in the imatinib group and 91.5% in the
IFN group (P G 0.001), with a CCyR of 76.2% compared with
14.5%.40 On the basis of the efﬁcacy seen in these studies,
imatinib gained approval from the US Food and Drug Admin-
istration (FDA) for the treatment of patients who had failed IFN
(2001) and for newly diagnosed patients in 2003. Subsequent
updates of the IRIS study at 60 months conﬁrmed these results.
Overall survival in the patients treated with ﬁrst-line imatinib
was 89%, a revolutionary improvement over previous IFN-based
regimens. No survival difference was demonstrated compared
with the IFN/cytarabine arm because most IFN patients crossed
over to imatinib for intolerance or lack of efﬁcacy.41
Single-center studies had suggested that increasing imatinib
from 400 to 800 mg/d could improve response rates. However,
randomized comparisons failed to conﬁrm these initial results.42
More recently, the German CML IV study showed a signiﬁcant
difference in the rate of mismatch repair (MMR) in favor of
higher doses of imatinib. It has been suggested that the more
ﬂexible dosing regimen in this study led to an overall higher dose
intensity and a superior result.43 At this point, the standard dose
of imatinib for newly diagnosed patients remains 400 mg daily,
and the drug remains a viable option for newly diagnosed
patients in the chronic phase.42 Imatinib, however, falls short of
effectively treating most patients in AP/BC.
Dasatinib
Inhibitors targeting Src kinases were the goal of Lombardo
et al44 when they discovered a dual-Src/ABL kinase inhibitor
initially referred to as BMS-354825 and now known as dasatinib
(Sprycel; Bristol-Myers Squibb). Dasatinib binds with high af-
ﬁnity to both ABL and the SRC kinase in the ATP-binding site,
translating to an ABL inhibition potency 300 times that of
imatinib in biochemical and cell proliferation assays. In addition
to SRC-family kinases, c-KIT, PDGFR->/A, and the ephrin re-
ceptor kinases are also inhibited by dasatinib.45 Uniquely, this
TKI binds ABL in both the active and inactive states, leading to a
more complete inhibition regardless of protein conﬁrmation.46
Dasatinib dose escalation studies were conducted in a co-
hort of 84 patients across all CML disease phases including a
minority with Ph+ acute lymphoblastic leukemia (ALL). A
maximum tolerated dose for dasatinib was not determined, but
importantly, patients who enrolled after previous imatinib in-
tolerance showed no similar toxicities.47 Efﬁcacy of this phase I
trial established 70 mg twice daily as the optimal dose for further
studies. The phase II trials for Src/ABL Tyrosine kinase inhibi-
tion Activity Research Trials of dasatinib (START) were con-
ducted separately for each disease phase. Dasatinib demonstrated
a robust and durable response in CP (CHR, 87%; MyCR, 52%)
and a progression-free survival of 92% at 8 months.48 Impres-
sive responses were seen in AP (MCyR, 33%) and BC (MCyR,
31% myeloid and 50% lymphoid); however, these responses
were much less durable than those in CP.49,50 In 2006, the FDA
granted approval of dasatinib at 70 mg twice daily for refractory
CML patients. Further dose optimization studies led recom-
mendations of 100 mg once daily for CP-CML,51,52 whereas
70 mg twice daily remained the dose for advanced CML.53
Nilotinib
To overcome imatinib resistance, nilotinib (AMN107/
Tasigna; Novartis) was rationally designed based on a thorough
analysis of the ABL-imatinib complex to increase binding af-
ﬁnity. Nilotinib is more selective than imatinib, favoring ABL
inhibition over the 2 other target kinases KIT and PDGFR.54
Nilotinib is 10 to 50 times more potent than imatinib and is an
inhibitor of many BCR-ABL mutants that are resistant to ima-
tinib.54,55 Phase I studies for nilotinib in imatinib-resistant CML
or Ph+ ALL patients revealed signiﬁcant activity in the chronic
Woessner et al The Cancer Journal & Volume 17, Number 6, November/December 2011
478 www.journalppo.com * 2011 Lippincott Williams & Wilkins
Copyright © 2011 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
41
phase (CHR, 92%; CCyR, 35%) and acceptable responses in the
accelerated phase, whereas results in the blastic phase were
disappointing, recapitulating the imatinib experience.56 An ad-
ministration of 400 mg twice daily emerged as the phase II dose.
Subsequent phase II studies in CP and AP reported MCyR of
48% and 29%, respectively.57,58 Nilotinib was approved in 2007
for CP and AP-CML. Recent follow-up of these patients indi-
cates that nilotinib provides a rapid and durable response in these
disease phases, especially in patients with prior suboptimal re-
sponse to imatinib.27,59
Resistance to Currently Approved TKIs
Despite the promise of TKIs in treating CML, drug resis-
tance does occur. Resistance can be primary (failure of a newly
diagnosed patient to achieve satisfactory response to drug) or
secondary/acquired (failure of a patient on treatment who ini-
tially responded to maintain this response). Tyrosine kinase in-
hibitor failure has been linked to mutations in the ABL kinase
domain that impair drug binding, increased BCR-ABL expres-
sion, and changes in drug efﬂux transporters that result in low
intracellular drug concentrations, particularly with imatinib.60,61
These changes can occur during progression to advanced disease
phases, but they do not, in and of themselves, cause progres-
sion.1 In vitro mutagenesis screens have been used to proﬁle
TKIs. These studies revealed the broadest activity for dasatinib,
followed by nilotinib, whereas imatinib has extensive gaps in
coverage, consistent with clinical data.62,63 On the basis of in
vitro proﬁles, we and others have developed heat maps of pre-
dicted in vivo activity.64 However, it is important to note that the
in vivo response is more complex, involving additional para-
meters such as plasma protein binding and plasma peak and
trough drug concentrations.65 As a result, the correlation be-
tween in vitro predictions and clinical responses is relatively
weak,66,67 with the notable exception of the T315I mutant, which
is resistant to all currently approved TKIs. This poses a signiﬁ-
cant challenge to therapy because the T315I mutation is reported
to represent 15% to 20% of all mutations.68
Tyrosine kinase inhibitors have transformed a previously
fatal disease into a manageable chronic condition, but drug
discontinuation usually results in disease recurrence, even in
patients with profound responses such as MMR or ‘‘PCR-
undetectable’’ CML, although rare exceptions may exist.69,70
Thus, drug treatment must continue indeﬁnitely, a signiﬁcant
drawback to current TKI therapy. Consistent with these clinical
observations, there is evidence that all 3 agents fail to eliminate
primitive CML cells and that the bone marrow environment is a
potential safe haven for these cells.71 Taken together, this sug-
gests that minimal residual disease may be beyond the reach of
our current TKI-based therapeutic arsenal. This is often referred
to as disease persistence.
Second-Generation TKIs in First-Line Therapy
Treatment advantages of second-generation TKIs over
imatinib were suggested during phase II studies; additional trials
comparing these inhibitors were quickly planned and executed.
The phase III trial, Evaluating Nilotinib Efﬁcacy and Safety in
Clinical TrialsVNewly Diagnosed Patients, compared nilotinib
300 or 400 mg twice daily and imatinib (400 mg once daily).
After 1 year, MMR for either nilotinib dose (43%Y45%) was
nearly double that of imatinib, and CCyR was signiﬁcantly
higher in the nilotinib cohorts (78%Y80% vs 65%).28 In addition,
nilotinib was superior in progression-free survival. As a result,
the FDA granted accelerated approval of nilotinib in June 2010
for newly diagnosed CML patients.72
The Dasatinib versus Imatinib Study in Treatment-Naive
CP-CML Patients (DASISION) trial tested dasatinib at 100 mg
daily versus imatinib 400 mg daily in newly diagnosed chronic
phase patients. This report indicated a comparable advantage as
seen in the Evaluating Nilotinib Efﬁcacy and Safety in Clinical
TrialsVNewly Diagnosed Patients trial regarding MMR for
dasatinib over imatinib (46% vs 28%) and CCyR (77% vs
66%).26 Progression-free survival was also improved, although
the difference failed to reach statistical signiﬁcance. Regulatory
approval of dasatinib for newly diagnosed CP-CML patients was
granted in October 2010.
Adverse Effects of Currently Approved TKIs
A comprehensive appreciation of TKI-related toxicities is
beyond the scope of this review. Hematologic toxicity is com-
mon and correlates with disease state, being more frequent in
patients with advanced disease compared with newly diagnosed
patients. It is generally believed that this reﬂects the more limited
reserve of normal hematopoiesis in patients with long-standing
or more aggressive CML. Nonhematologic toxicity is diverse
and dependent on the speciﬁc TKI. The good news is that these
toxicities are largely nonoverlapping, which implies that cross-
intolerance to all 3 approved TKIs is rare. For a comprehensive
and detailed review of toxicity, the reader is referred to a recent
review.73 Importantly, annual updates of the IRIS study, as well
as independent studies, conﬁrmed the safety of long-term ima-
tinib therapy in the sense that grades 3 to 4 toxicities are rare, and
no new and unexpected adverse effects became apparent with
longer follow-up.41,74 The body of data available for dasatinib
and nilotinib is more limited, and it will be important to remain
vigilant as therapeutic time increases for these drugs.
NOVEL AGENTS
ATP-Competitive ABL Inhibitors Without Activity
Against T315I
Several TKIs have been developed that exhibit a target
spectrum similar to the approved drugs, although they are dis-
tinct in off-target effects. The most advanced of these drugs is
bosutinib (SKI-606; Wyeth), originally developed as a Src ki-
nase inhibitor.75 Bosutinib has shown inhibitory activity in CML
cell lines and primary cells and has demonstrated tumor re-
gression in CML xenograft models. Unlike approved TKIs,
bosutinib does not inhibit c-Kit or PDGFR.76 Phase I and II
studies revealed drug activity in patients who failed imatinib.
However, as expected, efﬁcacy in patients who failed a second-
generation TKI was lacking. A phase III study did not meet the
primary end point (ie, superior rates of CCyR at 12 months in
comparison with imatinib 400 mg daily). Current speculation
attributes lack of efﬁcacy to insufﬁcient dose intensity triggered
by dose interruptions due to diarrhea, a common, but transient
adverse effect that should have been managed with supportive
care. Bosutinib could possibly add to the therapeutic arma-
mentarium as another drug with a unique adverse effect proﬁle.
However, it does not address the problems of the T315I mutant
and BCR-ABLYindependent resistance. Overall, the future of
bosutinib is unclear.77
T315I Active Inhibitors
The most advanced third-generation inhibitor of BCR-ABL
is ponatinib (AP24534; Ariad).78 Unlike all approved TKIs,
ponatinib is effective against the T315I mutant as well as a large
sample of other mutants previously detected in patients with
clinical TKI resistance.68 In vitro screens revealed no mutational
vulnerabilities in BCR-ABL, suggesting that ponatinib may be
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the ﬁrst true ‘‘pan-BCR-ABL’’ TKI. This drug also inhibits other
kinases including FLT3, FGFR, vascular endothelial growth fac-
tor receptor (VEGFR), c-Kit, and PDGFR.79,80 Ponatinib showed
signiﬁcant activity in a phase I study of patients with Ph+ leukemia,
mostly CML, who had failed other TKIs. Interestingly, responses
were most impressive in patients with the T315I mutation,
turning a poor prognostic factor into a favorable one.81 Ponatinib
is currently in phase II clinical trials (PACE trial, Ponatinib Ph+
ALL and CML Evaluation). PACE is a global, single-arm clin-
ical study including patients in all disease phases of CML and
Ph+ ALL. Given its activity against the T315I mutant, ponati-
nib may well replace nilotinib and dasatinib in salvage therapy.
A phase III study for ponatinib in ﬁrst-line therapy is in the
planning stage.
Aurora kinases are serine/threonine kinases known to reg-
ulate mitosis.82 Because of their role in cell cycle progression
and the fact that they are overexpressed in leukemias and solid
tumors,83 aurora kinases make attractive targets in CML thera-
peutic development. Several compounds with activity against
ABL mutants, including T315I, were developed and have en-
tered clinical trials. Among these, the most tested candidate is
AT9283 (Astex Therapeutics) with activity against ABL, as well
as Aurora A/B kinases, and Janus kinases 2/3 (JAK2 and
JAK3).84 Preclinical efﬁcacy was demonstrated in mouse mod-
els leading to initiation of clinical trials.84 Phase I and IIa clinical
trials were completed in October 2010, and a recommended
phase II dose was determined (NCT00522990). Danusertib,
another Aurora kinase inhibitor, is currently in phase I studies
in patients with refractory Ph+ leukemias.85 Results have not
yet been published. Two other Aurora kinase inhibitors with ac-
tivity against T315I mutant ABL, MK-0457 and XL228, failed in
clinical trials (NCT00464113) for various reasons, including
toxicity.86 The clinical efﬁcacy of compounds inactive against
T315I, but which inhibit other pathways (like the Src-family
kinases) remains to be determined. Table 1 provides an overview
of new compounds in development for Ph+ leukemias.
Allosteric/Non-ATP Competitive Inhibitors
DCC-2036 (Deciphera) is an inhibitor of BCR-ABL that
forces a conformational change of ABL on drug binding. ABL
can exist in either an active (type I) or inactive (type II) con-
formation based on phosphorylation status. Structure-based
design of DCC-2036 elucidated a ‘‘switch-pocket’’ in ABL,
inducing a stable and inactive state.87 DCC-2036 inhibits ABL
in a non-ATP competitive manner; it also inhibits Src, Lyn, Fgr,
Hck, Flt3, and Tie2 but spares Kit. Based on efﬁcacy in pre-
clinical studies, a phase I trial has been initiated and is currently
recruiting.
An allosteric, non-ATP competitive inhibitor of BCR-ABL
is GNF-2 (Genomics Novartis Foundation), which was discov-
ered during kinase activity screening.88 GNF-2 is hypothesized
to bind at the myristoyl binding cleft of BCR-ABL, distant from
TABLE 1. Drugs Developed for CML Therapy With Activity Against ABL-Kinase and Other Kinases Listed
Novel ABL Inhibitors
Inhibitor Non-ABL Kinase Target(s) T315I Status References
DCC-2036 Src, Lyn, Fgr, Hck, Flt3, Tie2 Active Phase I/II NCT00827138
GNF compounds ABL only Active Preclinical *
ON012380 ABL only Active Preclinical †
PPY-A ABL only Active Preclinical ‡,§
SGX393 ABL only Active Preclinical ¶
XL228 Aurora A/B, FAK, Src Active Phase IVterminated NCT00464113
MK-0457 Aurora A-C, Flt3 Active Phase IIVterminated NCT00405054
AT9283 Aurora A/B, JAK2/3 Active Phase I/II NCT00522990
Danusertib Aurora A-C, Ret, Trk-A, FGFR-1 Active Phase II NCT00335868
Ponatinib Flt3, FGFR, VEGFR, c-kit, PDGFR Active Phase II NCT01207440
Bafetenib Lyn NA Phase IVdevelopment unlikely NCT00352677
AP23464 Src family Active Preclinical ||
Bosutinib Src, TEC, STE20, CAMK2G NA Phase I/II/III NCT00811070, NCT00261846
DSA compounds Src Active Preclinical **
PD166326 Src NA No trials or recent reports ††
Saracatinib Src family NA Not in trials for CML ‡‡
HG-7-85-01 Src, PDGFR, VEGFR, Flt3,
Ret, Tie2, Kit, DDR1, b-raf
Active Preclinical §§
*PLoS One. 2011;6:e15929.
†Proc Natl Acad Sci U S A. 2005;102:1992Y1997.
‡Chem Biol Drug Des. 2007;70:171Y181.
§Med Res Rev. 2011;31:1Y41.
¶Proc Natl Acad Sci U S A. 2008;105:5507Y5512.
||Chem Biol Drug Des. 2010;75:223Y227.
**Cancer Res. 2009;69:2384Y2392.
††Blood. 2005;105:3995Y4003.
‡‡Expert Opin Investig Drugs. 2010;19:931Y945.
§§Blood. 2010;115:4206Y4216.
NA indicates not active.
Woessner et al The Cancer Journal & Volume 17, Number 6, November/December 2011
480 www.journalppo.com * 2011 Lippincott Williams & Wilkins
Copyright © 2011 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
43
the active site of BCR-ABL. GNF-2 has exceptional speciﬁcity
for BCR-ABL, does not inhibit c-Kit, PDGFR, or other kinases
(63 tested), and is nontoxic toward nonYBCR-ABLYexpressing
cells.88 GNF-2 has been found to enhance imatinib activity against
BCR-ABL, whereas a GNF-2 analog (21a-I) was found to synergize
with dasatinib against the T315I mutant.89 Other GNF analogues
are in development,90,91 but none are currently in clinical trials.
The Essential BCR Coiled Coil
Oligomerization of BCR-ABL through the coiled-coil
domain (Fig. 1) is essential for oncogenicity,92,93 making this
region an attractive target for therapeutic development.94 Non-
small-molecule inhibitors targeting the BCR coiled-coil are exciting
alternatives that disrupt BCR-ABL oligomerization and activa-
tion. We have recently reported the disruption of BCR-ABL via a
rationally designed mutant coiled-coil peptide.95 Such peptides
may reduce the risk of acquired resistance due to the numerous
contact points between the coiled-coil and the protein or because
peptides are not typical substrates for drug efﬂux transporters
whose overexpression may lead to resistance.85 Delivery strat-
egies for peptide therapeutics to the CML cell are a current focus
of our laboratory.
Degrading BCR-ABL
A natural compound in vegetables, PEITC, was found to
kill T315I harboring cells in culture and from patient samples.96
PEITC induces oxidative stress in CML cells leading to degra-
dation of BCR-ABL. Another degradation strategy involves a
novel ubiquitin cycle inhibitor, WP1130, reported to rapidly
induce ubiquitination of BCR-ABL resulting in protein reloca-
tion into aggresomes, rendering it inactive. Both imatinib-
sensitive and -resistant CML cells initiated apoptosis in response
to WP1130.97
Hsp90 (heat shock protein 90) inhibitors geldanamycin
and 17-AAG were shown to induce degradation of BCR-ABL
protein in vitro.98,99 Mechanistically, after dissociation of Hsp-90
from client proteins, Bag1 (B-cell lymphoma-2 [Bcl-2]Yassociated
athanogene-1) mediates BCR-ABL localization to the proteasome
and stimulates its degradation via an E3-ligaseYdependent mech-
anism.100 However, clinical trials in CML were disappointing.
Immunotherapy
In addition to small molecules, immunologic targeting of
BCR-ABL, rather than kinase inhibition, may be effective. In-
terferon may function by inducing cytotoxic T-cell responses
against myeloid antigens.101 A more speciﬁc approach is vac-
cines targeting the BCR-ABL junction.102,103 Despite some
encouraging results, the efﬁcacy of this approach remains un-
proven in the absence of a prospective randomized trial. Anti-
bodies to the BCR-ABL junction have also been produced.104,105
Updates to these are smaller fragments of antibodies such as
iDabs,106 including those speciﬁc to BCR-ABL,107 and small
FIGURE 1. p210 BCR-ABL functional domains and effects of downstream signaling. BCR-ABL signaling leads to enhanced proliferation,
reduced apoptotic potential, and altered cell adhesion. Contributions from both BCR and ABL domains on downstream signaling are
illustrated. Dashed lines indicate additional intermediate signaling steps not detailed in this ﬁgure. ABD indicates actin binding
domain; CC, coiled-coil; DBD, DNA binding domain; DH, Dbl homology; PH, Pleckstrin homology; S/T kinase, serine/threonine
kinase; SH2 or SH3, Src homology 2/3; Y kinase, tyrosine kinase. Figure courtesy of Andrew Dixon.
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antibody mimics or monobodies.108 The clinical utility of these
antibodies is unclear.
TARGETING CML STEM CELLS AND THEIR
MICROENVIRONMENT
Stem Cell Niche
In vitro, TKIs are known to have antiproliferative effects
on primitive CML cells, but they do not induce apoptosis. This
may explain why TKIs fail to eliminate CML stem cells in
vivo, evident by disease persistence and the inability to discon-
tinue therapy. We have reported that primitive human CML stem
cells are not dependent on BCR-ABL, suggesting that, on TKI
challenge, CML stem cells rely on survival signals other than
BCR-ABL. It is likely that these signals are provided by the
microenvironment. It follows that therapies that only biochem-
ically target BCR-ABL will be unable to eliminate CML stem
cells.71 Cytokines, chemokines, and the extracellular matrix,
collectively referred to as the microenvironment, may activate
signaling pathways involved in survival. Therapeutic strategies
that target stem cells within this context hold promise to elimi-
nate residual leukemia, including cytokine antagonists, adhesion
molecule antagonists, and inhibitors of survival and self-
renewal.109
The Hedgehog (Hh) signaling pathway has been implicated
in hematopoietic stem cell renewal. Consistent with a critical role
of Hh for CML pathogenesis, lack of Smoothened, an essential
component of the pathway, was shown to attenuate CML in
murine models.110 Similarly, the Hedgehog inhibitor LDE225 in
combination with nilotinib resulted in elimination of CML stem
and progenitor cells.111 Several Hedgehog inhibitors, including
PF-04449913, for hematologic malignancies are also in clinical
development.112Wnt/A-catenin signaling has also been shown to
play a critical role in hematopoietic stem cell self-renewal and
may offer therapeutic opportunities.113
AKT, a well-established downstream target of BCR-ABL,
phosphorylates the Foxo3a transcription factor, leading to its
exclusion from the nucleus and suppression of transcription.
Despite this, Foxo3a is nuclear in primitive CML cells. Recent
data have suggested that TGF-A signaling may be responsible
for this unexpected ﬁnding, and it has been inferred that this
may allow CML stem cells to remain in a quiescent state, despite
BCR-ABL activity. If so, this would suggest that inhibiting TGF-
A may push the critical cells into cycle, thereby rendering them
susceptible to BCR-ABL inhibition. Efﬁcient depletion of CML
in vivowas found with a combination treatment using imatinib, a
TGF-A inhibitor, and Foxo3a depletion.114
Yet another strategy is to interfere with stem cell hom-
ing. For example, CXCR4 is a receptor for the chemokine
SDF-1 (stromal-derived factor 1), and plays a role in homing
TABLE 2. A Summary of Current Combination Therapies to Improve CML Treatment Outcomes in Clinical Trials
Combination Therapies for CML
TKI Combination Second/Third Drug Function of Non-TKI Stage Reference
Any TKI Arsenic trioxide Multiple* Phase I NCT01397734
BOS/DAS PF-04449913 Hh inhibitor Phase I NCT00953758
DAS BMS-833923 smo inhibitor Phase I/II NCT01218477
DAS Vorinostat HDAC inhibitor Phase I NCT00816283
IM Cytarabine or IFN DNA synthesis or multiple† Phase III NCT00219739
IM IFN Multiple† Phase II/IV NCT00573378, NCT00390897
IM IFN/granulocyte macrophage colony
stimulating factor (GM-CSF)
Multiple†/GM differentiation Unknown NCT00050531
IM Valproic acid HDAC inhibitor Phase II NCT01011998
IM Homoharringtonine (HHT) Protein synthesis inhibitor Phase II NCT00114959
IM Vatalanib (PTK 787) VEGF, c-KIT, PDGFR inhibitor Phase I/II NCT00088231
IM Zileuton Alox5 inhibitor Phase I NCT01130688
IM NIL BCR-ABL Phase II NCT00769327
IM Arsenic trioxide Multiple* Phase II NCT00250042
IM Lonafarnib Farnesyl-OH-transferase inhibitor Phase I NCT00047502
IM Tipifarnib Farnesyltransferase inhibitor Phase I NCT00040105
IM Vincristine/dexamethasone Microtubule inhibitor/immunosuppressant Phase II NCT00763763
IM GM-K562 - biologic Immune surveillance initiation Phase II NCT00363649
IM Everolimus mTOR inhibitor Phase I/II NCT00093639
IM Hydroxychloroquine Lysosomal acidification/autophagy
inhibitor
Phase II NCT01227135
IM TALL-104 - biologic Modified therapeutic T cell Phase II NCT00415909
NIL IFN Multiple† Phase I/II NCT01220648, NTC01294618
*Proapoptotic/antiproliferative.
†Inhibits angiogenesis migration and proliferation.
BOS indicates bosutinib; DAS, dasatinib; GM, granulocyte and macrophage; HDAC, histone deacetylase; Hh, hedgehog; IM, imatinib; mTOR,
molecular target of rapamycin; NIL, nilotinib; PDGFR, platelet-derived growth factor receptor; smo, smoothened; TKI, tyrosine kinase inhibitor; VEGF,
vascular endothelial growth factor.
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of CD34+ stem cells to the bone marrow microenvironment.
Imatinib inhibition of BCR-ABL restores the CXCR4 interac-
tion with SDF-1, leading to the migration and attachment of
CML cells to the bone marrow microenvironment. However, a
CXCR4 antagonist, AMD3465, partially inhibited cell migra-
tion to mesenchymal cells in coculture conditions. Similar results
were seen with QLT0267, an integrin signaling inhibitor.115
Drug Combinations and Synthetic Lethality
Although stem cells express, but are not addicted to, BCR-
ABL it may still be possible to manipulate other pathways which
assume an essential role in response to ABL inhibition. This idea
of synthetic lethality for cancer therapy is not new but has re-
cently received more attention in the CML ﬁeld propelled by
emerging data demonstrating BCR-ABLYindependent disease
persistence on TKI therapy. In an RNAi-based screen for dys-
regulated genes in response to imatinib therapy, theWnt pathway
emerged as the viable target for a second hit.116 Other critical
pathways involved in disease progression or leukemic cell function
have become attractive targets to augment BCR-ABL inhibition.
For example, inhibition of ATG7,117 MUC1,118 Alox5,119 and
mTOR120 have all been investigated in preclinical studies be-
cause they do not cause loss of hematopoietic stem cell function
but instead target the leukemic clone in combination with TKIs.
A list of recent clinical trials for combination therapies can be
found in Table 2.
Finally, transcription factors such as STAT5 can mediate
resistance to TKIs.121 Some patients in BC-CML have signiﬁ-
cant down-regulation of signal transducers and activators of tran-
scription (STAT) inhibitor proteins, potentiating cell survival and
residual disease.122 A new STAT5 inhibitor, pimozide, is able
to decrease STAT5 and its target genes, resulting in growth in-
hibition of Ph+ patient samples independently of ABL muta-
tions.123 The precise mechanism of action of this compound is
not known. For a comprehensive discussion on other signal
transduction pathways in CML, the reader is referred to the
referenced chapter.124
CONCLUSIONS
The rational design of drugs targeting BCR-ABL has made
CML a manageable disease, resulting in prolonged survival for
most patients. Mutations resulting in resistance to imatinib have
driven development of the second-generation TKIs nilotinib and
dasatinib. These inhibitors are active against a broad spectrum
of BCR-ABL mutants, with the notable exception of the T315I
‘‘gatekeeper’’ mutant, which, in turn, has led to third-generation
inhibitors. The most advanced of these is ponatinib, which has
been termed a pan-BCR-ABL inhibitor, as it does not have identi-
ﬁable gaps in BCR-ABL coverage. As complete ablation of BCR-
ABL activity becomes a reality, the question arises whether we
will see BCR-ABLYindependent resistance emerge as a unifying
feature of TKI failure. As the ﬁeld has focused on the role of
kinase domain mutations, relatively little is known about these
mechanisms.
On the other side of the response spectrum is minimal re-
sidual leukemia despite prolonged TKI therapy. Although the
relapse rate in this population of patients is very low, the need
for continued treatment has major health and economic impli-
cations, and it remains possible that we will see unexpected late
adverse effects in patients after decades of TKI therapy. Recent
evidence suggests that primitive CML cells survive despite in-
hibition of BCR-ABL, suggesting a biologic barrier to disease
eradication by TKIs.71 We contend that eradicating CML will
require targeting the stem cell niche. Several pathways have
emerged as potential targets, and a clear winner has not yet been
identiﬁed. In many respects, CML has served as a paradigm for
cancer therapy, and it is likely that this will continue to be the
case as we start to transform profound responses into deﬁnitive
‘‘cures.’’
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ABSTRACT: Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by
expression of the fusion gene BCR-ABL following a chromosomal translocation in the
hematopoietic stem cell. Therapeutic management of CML uses tyrosine kinase inhibitors
(TKIs), which block ABL-signaling and eﬀectively kill peripheral cells with BCR-ABL. However,
TKIs are not curative, and chronic use is required in order to treat CML. The primary failure for
TKIs is through the development of a resistant population due to mutations in the TKI binding
regions. This led us to develop the mutant coiled-coil, CCmut2, an alternative method for BCR-
ABL signaling inhibition by targeting the N-terminal oligomerization domain of BCR, necessary
for ABL activation. In this article, we explore additional pathways that are important for
leukemic stem cell survival in K562 cells. Using a candidate-based approach, we test the
combination of CCmut2 and inhibitors of unique secondary pathways in leukemic cells.
Transformative potential was reduced following silencing of the leukemic stem cell factor Alox5
by RNA interference. Furthermore, blockade of the oncogenic protein MUC-1 by the novel
peptide GO-201 yielded reductions in proliferation and increased cell death. Finally, we found that inhibiting macroautophagy
using chloroquine in addition to blocking BCR-ABL signaling with the CCmut2 was most eﬀective in limiting cell survival and
proliferation. This study has elucidated possible combination therapies for CML using novel blockade of BCR-ABL and
secondary leukemia-speciﬁc pathways.
KEYWORDS: CML, coiled-coil, CCmut2, zileuton, GO-210, chloroquine, combination therapy, K562, BCR-ABL
■ INTRODUCTION
Chronic myeloid leukemia (CML) manifests following a
reciprocal chromosomal translocation between the breakpoint
cluster region (BCR) gene and the Abelson tyrosine kinase
(ABL) gene [t(9;22)(q34;q11)] in the hematopoietic stem
cell.1,8 Upon expression of the BCR-ABL fusion protein (a
constitutively active tyrosine kinase), a leukemic stem cell
(LSC) is generated, driving LSC self-renewal and expansion of
BCR-ABL-expressing lineages including myeloid and lymphoid
blasts.9,10 Tyrosine kinase inhibitors (TKIs) are competitive
inhibitors for the ATP binding site of ABL and make up the
therapeutic arsenal for disease management.3 We have
previously described a unique interfering peptide, CCmut2,
able to disrupt BCR-ABL homo-oligomers.4 Moreover,
oligomerization is necessary for ABL activation.11 Interestingly,
oligomeric disruption of trans-auto phosphorylation by CCmut2
exacts its activity via the coiled-coil domain in BCR, leading to
an overall similar eﬀect seen with TKIs: reduced phosphor-
ylation of ABL and downstream targets STAT5 and Crk-L,
induction of apoptosis, and reduction in proliferation.4,12
Single-agent TKI therapy for CML has eﬀectively limited
disease progression for the majority of patients.3 However,
resistance to therapy and persistence of a subset of leukemic
cells despite TKI activity13 demonstrate the necessity for
multiple-agent therapy, especially to address the LSC
population.10,14 Previous reports have demonstrated enhanced
cytotoxicity when using a TKI in combination with a second
agent targeting a BCR-ABL independent pathway,6,7,15,16 two
of which have moved into clinical trials (NCT01130688;
NCT01227135). Though these are promising developments to
circumvent molecular failure, the TKI component will likely
continue to have problems with resistance.2,17,18 The CCmut2
may be less prone to mutational resistance selection, mainly
due to the highly speciﬁc and selective nature of a large
interaction domain.4 This draws a parallel similar to diﬀerences
in speciﬁcity between small molecules versus antibodies for
cancer therapy.19 Therefore, a multiple-agent therapeutic
approach involving the CCmut2 may be superior to TKI
single-agent therapy (Figure 1A).
We were interested in discovering whether enhanced
apoptotic activation or reduction in proliferation could be
achieved by combining CCmut2 with secondary agents having
independent mechanisms of action.20 Here, we detail the results
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of this peptide (delivered as a gene and transcribed in vitro) in
combination with additional small molecule or biologic agents.
Secondary target candidates were selected based on previous
reports of drugs known to be eﬀective when used in
combination with imatinib, and those drugs were found to be
eﬀective only against leukemic (vs normal hematopoietic)
cells.18 Additional criteria led to the selection of key proteins
involved in CML progression, namely, ATG7,7 MUC-1,21 and
Alox5.15 These targets were chosen because they do not cause
loss of hematopoietic stem cell function. RNA interference
(RNAi) or molecular disruption of these pathways was
investigated.
The selection of and rationale for pathways and molecular
agents for combination with the CCmut2 are as follows: (1)
ATG7 and chloroquine (CQ). Macroautophagy (referred to as
autophagy from this point on) is a cellular process activated in
starvation conditions to improve recycling of cell components
and enhance cell survival.22 This pathway becomes important in
cancer as a mechanism for cell escape elimination when treated
with anticancer agents.23 ATG7 is necessary for autophagy, and
its inhibition blocks the formation of the autophagosome, an
early step in the autophagy process, while CQ inhibits
lysosomal acidiﬁcation, which eliminates the breakdown of
products contained in the autophagosome blocking cellular
autophagy in the later stages.23 Speciﬁcally in CML, a
Figure 1. (A) Model of multiagent vs single agent therapy for CML. The BCR-ABL translocation is thought to arise in the stem cell population,
giving rise to leukemic stem cells (LSC). If untreated, the progeny from the LSC expressing the constitutively active tyrosine kinase fusion protein
BCR-ABL give rise to expanded cell populations, which is fatal to the patient. Current clinical care uses targeted therapy against the kinase ABL,
which does treat the disease. However, mutations within the ABL gene can generate a resistant population, which can lead to leukemic cell survival.
Using a BCR-targeted inhibitor is hypothesized to decrease the possibility of resistance, and adding a second agent can enhance cell killing. (B) Left:
a CML cell and a simpliﬁed disease pathway of CML (black arrows). Current treatment modalities (TKIs) can act to reverse these eﬀects; however, a
potential escape from conventional therapy through the autophagy pathway is depicted with gray arrows. Right: experimental strategies for
addressing untreated or resistant populations of CML disease states. (1) The CCmut2 targets the BCR domain with an eﬀect on in vitro cells similar to
that of TKIs; (2) the oncoprotein MUC-1C can be disrupted by RNA interference (RNAi) or the peptide inhibitor GO-201; (3) autophagy
blockade can be achieved by chloroquine (CQ) or by RNAi targeting Atg7; (4) the LSC enhancing factor Alox5 is inhibited by targeting 5-LO
metabolism with zileuton (zil) or degrading the Alox5 message using RNAi.
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combination of imatinib and CQ enhance leukemic cell killing.7
For this reason, we were interested in blocking autophagy in
combination with CCmut2. (2) Alox5 and zileuton (zil). The
arachidonate 5-lipoxygenase (Alox5) gene product 5-lip-
oxygenase (5-LO) is responsible for leukotriene synthesis
from arachadonic acid (AA); reports indicate increased AA in
CML cells.5,18 This enhances proliferation and inhibits
diﬀerentiation in leukemic stem cells (with Bcr-Abl). Knockout
of Alox5 or treatment with a 5-LO inhibitor (zil) is known to
change the proliferative capacity of CML cells.15,24,25 (3)
MUC-1C and GO-201. MUC-1 is a known oncogene widely
expressed in cancer cells in general and in CML cells
speciﬁcally.21,26 Kufe and colleagues have reported the
association of the cytoplasmic portion of MUC-1 (MUC-1C)
with BCR-ABL, enhancing the oncogenic cytoplasmic signaling
of BCR-ABL. Furthermore, the use of GO-201, a speciﬁc
inhibitor of MUC-1C with imatinib, has shown reduction in
proliferation and induced diﬀerentiation in CML cells.6,16
These interactions are depicted in Figure 1B.
In this article, these agents in combination with CCmut2 were
found to improve therapeutic potency in K562 cells. Trans-
formative ability was most reduced by inhibiting protein
expression of Alox5 using RNAi in combination with the
CCmut2. Reduction in proliferative capacity resulted largely due
to CCmut2 alone but was further decreased by GO-201. Finally,
increased caspase activity was seen with CQ and CCmut2, while
combinations of either GO-201 or CQ and CCmut2 enhanced
the apoptotic and necrotic cell population as visualized by
Annexin-V and 7-AAD staining.
■ MATERIALS AND METHODS
Constructs. RNAi constructs were targeted against human
Atg7, Alox5, MUC-1, or luciferase control. Target sequences
for Atg7 or MUC-1 were derived from previous reports,6,7
while the Alox5 (NM_000698) RNAi sequence was designed
using BLOCK-iT RNAi Designer (Life Technologies, Grand
Island, NY). RNAi sequences are as follows: Alox5 (5′-
ggaatgacttcgccgactttg-3′); Atg7 (5′-cagtggatctaaatctcaaactgat-
3′);7 MUC-1C (5′-aagttcagtgcccagctctac-3′).6 Oligonucleotides
encoding short hairpins against the following transcripts were
synthesized at the University of Utah core facilities: Alox5 top
(5′- gatccggaatgacttcgccgactttggaagcttgcaaagtcggcgaagtcattccttt-
tttggaagc-3′) and bottom (5′- ggccgcttccaaaaaagg-
aatgacttcgccgactttgcaagcttccaaagtcggcgaagtcattccg-3′); Atg7
top (5′- gatccgcagtggatctaaatctcaaactgatgaagcttgatca-
gtttgagatttagatccactgttttttggaagc-3′) and bottom (5′-
g g c c g c t t c c a a a a a a c a g t g g a t c t a a a t c t c a a a c t g a t c a a g -
cttcatcagtttgagatttagatccactgcg-3′); MUC-1 top (5′-
gatccgaagttcagtgcccagctctacgaagcttggtagagctgggcactgaacttt-
tttttggaagc-3′) and bottom (5′- ggccgcttccaaaaaaaa-
gttcagtgcccagctctaccaagcttcgtagagctgggcactgaacttcg-3′). Top
and bottom strands were annealed and then cloned into the
Gene Silencer shRNA Expression Vector pGSH1-GFP
(Genlantis, San Diego, CA) according to the manufacturer's
instructions. The pEGFP-C1 parent plasmid was purchased
from Clontech laboratories (Mountain View, CA); the coiled-
coil (pEGFP-CC) or mutant coiled-coil (pEGFP-CCmut2) are
described elsewhere.4
Cell Lines and Transfections. Cells culture and trans-
fections were carried out as described previously.4 Brieﬂy, K562
cells were cultured in complete RPMI medium with 10% FBS,
1% Pen-Strep-Glut, and 0.1% Gentamycin (Life Technologies,
Grand Island, NY). Cells were maintained at 37 °C and 5%
CO2. DNA constructs were transfected with the Amaxa
nucleofection system (Lonza Bio, Basel, Switzerland), using 6
μg of DNA in 100 μL of Solution V with 2 million cells, and
then returned to complete RPMI medium.
Western Blotting. Cells were counted on a hemocytom-
eter, pelleted, and frozen at −80 °C overnight. Cell pellets were
resuspended in RIPA lysis and extraction buﬀer (Thermo
Scientiﬁc/Pierce Protein Biology Products, #89900, Kalamazoo,
MI). A BCA Protein assay was performed (Thermo Scientiﬁc,
#23225), and 10 μg of protein was loaded in each lane of a
denaturing gel. Standard Western blotting procedures were
used.4 Antibodies used to detect Atg7 (Sigma-Aldrich, #A2856,
St. Louis, MO), LC3A/B (Sigma-Aldrich, #L8918), MUC-1C
(Thermo Scientiﬁc, #MUC-1 Ab-5/HM-1630), Alox5 (Abcam,
#ab115764, Cambridge, MA), actin (Abcam, #ab1801), and
eIF4E (Cell Signaling Technology, #C46H6, Danvers, MA)
primary antibodies were used. HRP conjugated secondary
antibodies were anti-Armenian hamster (Abcam, #ab5745) or
anti-rabbit (Cell Signaling Technology, #7074). Quantiﬁcation
of bands using relative densitometry was completed using
AlphaView SA (Protein Simple, v3.0, Santa Clara, CA). For
LC3II/I ratios, background corrected sum values for each band
were calculated as a ratio to eIF4E control. Then LC3-II
percent control was divided by LC3-I percent control. This
gives a relative ratio of LC3-II to LC3-I conversion.
Colony Forming Assay. pGSH1 constructs expressing
shRNA sequences against Atg7, MUC-1, or Alox5 were
transfected and cultured 4 days to ensure knockdown. One
day following transfection, genticin reagent (Life Technologies)
was added at a concentration of 500 μg/mL in complete RPMI.
On day 4, a second construct was transfected (pEGFP-C1;
−CC; or −CCmut2). Dual-transfected cells were resuspended in
Iscove’s Modiﬁed Dulbecco’s Medium containing 2% FBS
(Stem Cell Technologies, Vancouver, BC, Canada), and 1,000
cells were seeded in Methocult H4230 methylcellulose medium
(Stem Cell Technologies). Imatinib mesylate (IM #CT-IM001,
Chemie-Tek, Indianapolis, IN) was added to untransfected
K562 cells in Methocult at the time of seeding. Transformation
potential was assessed 7 days after seeding cells by counting
colonies in 200 μM2.
Drug Treatments. In all cases, small molecule or peptide-
based inhibitors were added to transfected cells 6 h after
transfections unless otherwise noted. GO-201 (Sigma-Aldrich,
#G7923) is a well-described peptide inhibitor of MUC-1C27
and was used at a ﬁnal concentration of 5 μM in 1× PBS (Life
Technologies, #14190-144). Zileuton (Sigma-Aldrich, #Z4277)
is a small molecule inhibitor active against 5-lipoxygenase (the
protein product of Alox5) and was used at a ﬁnal concentration
of 20 μM dissolved in DMSO. Chloroquine (Sigma-Aldrich,
#C6628) is an inhibitor of lysosomal acidiﬁcation (autophago-
somal activation) and was used at a ﬁnal concentration of 10
μM.
Cell Proliferation. K562 cells were transfected with EGFP,
CC, or CCmut2, followed by drug treatment 6 h later. Trypan
blue exclusion4 was assessed 48 h after transfection to
determine cell proliferation/viability.
Caspase 3/7 Assay. Cells were transfected as indicated
above (in Cell Lines and Transfections) followed by drug
treatment 6 h later. Forty-eight hours following transfection,
cells were counted, pelleted, and frozen at −80 °C overnight.
Cells were resuspended, lysed, and processed according to the
Caspase Glo 3/7 manufacturer's instructions (Promega,
Madison, WI). Luminescence was measured after 1 h at 26
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°C on a SpectraMax M2 plate reader (Molecular Devices,
Sunnyvale, CA).
Annexin-V/7-AAD Assay. Cells were transfected and
treated as described above (in Cell Lines and Transfections)
followed by drug treatment 6 h later. At 48, 72, or 96 h, cells
were resuspended in 0.5 mL of Annexin-V binding buﬀer (Life
Technologies, #V13246) stained with 1 nM 7-AAD (Life
Technologies, # A1310) and a 1:20 dilution of Annexin-V-APC
(Life Technologies, #A35110). Samples were sorted using a BD
FACSCanto II ﬂow cytometer according to GFP positivity
(10,000 GFP events were collected). Cells were then sorted
according to apoptotic (Annexin-V) and necrotic (7-AAD)
markers. Data was further analyzed using FlowJo ﬂow
cytometry analysis software (Tree Star Inc., Ashland, OR).
Statistics. Data are expressed as the means ± SEM from at
least 3 independent experiments. Signiﬁcance of diﬀerences
between groups was assessed in GraphPad Prism 5 (GraphPad
Software, La Jolla, CA) using either a Student’s t test, two-way
ANOVA with a Bonferroni post-test, or one-way ANOVA with
Bonferroni post-test. A p-value of <0.05 was considered
signiﬁcant.
■ RESULTS
BCR-Based Inhibition of BCR-ABL with Alox5 Knock-
down Reduces the Transformation Potential of K562
Cells. 5-Lipoxygenase (5-LO), the protein product of Alox5,
mediates processes such as inﬂammation and oxidative stress
through leukotriene synthesis. Because of this, 5-LO antago-
nists are an important therapy for inﬂammatory diseases and
Figure 2. (A) Representative Western blot of protein expression for Atg7, MUC-1, and Alox5 after 96 h following transfection with pGSH1-shLUC-
GFP (left lane) compared to RNA interference targeting genes of interest (right lane). (B) Knockdown via RNAi is depicted based on
semiquantitative band densitometry for each construct compared to that of shLuc control. Each short-hairpin RNAi construct resulted in signiﬁcant
knockdown of its targets. Student’s t test, **p < 0.01; *p < 0.05; n = 3.
Figure 3. Colony forming assay of dual-transfected short-hairpin and experimental constructs reveals a signiﬁcant combination eﬀect of Alox5 and
CC or CCmut2. Two-way ANOVA and the Bonferroni post-test, *p < 0.05, n ≥ 3.
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have also been suggested for cancer therapy.28 Reports of
potential antiproliferative eﬀects in hematologic malignancies
from the loss of Alox5 or 5-LO inhibitors surfaced in the
1980s29,30 and recently were bolstered in a CML in vivo model
by data from Chen and colleagues.5,15,31
To determine the contribution of several pathways to
transformative ability (measured by colony forming cells),
selected pathways were disrupted by knockdown of key genes
regulating each pathway using shRNA expressing constructs.
Western blotting for protein products of Atg7, MUC-1, and
Alox5 demonstrated successful knock down of all targets
(Figure 2A, second lane of each pair) when compared to that in
control shRNA against luciferase control (Figure 2A, shLuc,
ﬁrst lane of each pair). These data are quantiﬁed using band
densitometry and expressed as percent shLuc (Figure 2B).
These constructs were then used in combination with GFP
control, wild-type coiled-coil (CC), or mutant coiled-coil
(CCmut2)4 in a week long transformation study. Transient
expression of shAlox5 and CC or CCmut2 resulted in signiﬁcant
reduction of colonies (Figure 3, shAlox5 group, far right bars)
compared to that in GFP control and shAlox5 dual expression
(Figure 3, shAlox5 group, third to right bar, gray).
Chloroquine Combinations Block an Upregulated
Autophagy Pathway Following BCR-ABL Inhibition.
Autophagy is a degradative process used by cells to break
down intracellular material via lysosomes. Autophagy can
promote or suppress oncogenesis depending on the cellular
context;22 however, induction of autophagy provides a survival
mechanism in BCR-ABL cells treated with imatinib (cells
undergoing stress; see Figure 1B).7,32 Though previous reports
indicated enhanced autophagy following the introduction of
kinase inhibitors,7,32,33 this pathway has not been previously
investigated following the expression of the CCmut2. Addition-
ally, since no reduction in transformative ability was observed
following the knockdown of Atg7, we proceeded to investigate
whether autophagy is activated following the transfection of
GFP, CC, or CCmut2. The conversion of microtubule associated
protein light chain 3 (LC3) from LC3-I to LC3-II was used to
monitor autophagy. This is the case when comparing lanes 3
and 4 or lanes 7 and 8. Because cellular levels of LC3-II are
indicative of the number of autophagosomes (e.g., an increase
in autophagy),34 increases in LC3-II protein expression were
measured by immunobloting. When no autophagy occurs, a
more prominent LC3-I band will be visible, indicating the
presence of the precursor and cytoplasmic LC3-I (i.e., LC3II/I
<1.0). This is visible in Figure 4, lanes 1−2 and 5−6. When
autophagy occurs, and inhibitors are added to eliminate LC3-II
breakdown via the lysosome, LC3-II becomes the prominent
band (i.e., LC3II/I >1.0).34,35
LC3-II/LC3-I ratios7,35 were calculated following exposure
to 5 μM imatinib (Figure 4, lanes 3 and 4) or transfections and
with or without CQ at 24 h (Figure 4, lanes 5−8). The data
represented in Figure 4 demonstrate little to no activation of
autophagy in untreated or GFP transfected K562 cells (Figure
4, lanes 1−2; 5−6). Autophagy is activated by inhibition of
BCR-ABL using either BCR or ABL inhibitors at 24 h (Figure
4, lanes 3−4; 7−8). Similar trends were seen at 12 h (data not
shown).
CQ and GO-201 Further Diminish the Proliferative
Capacity of K562 Cells beyond the Reductions Seen
Using CCmut2 Alone. MUC-1 is a membrane-bound
glycosylated phosphoprotein whose normal function protects
the body from chemicals/bacteria through its polarized
expression on epithelial cell surfaces.21 The cytoplasmic domain
of MUC-1, called MUC-1C, interacts with the BCR portion of
BCR-ABL to promote continued oncogenic signaling.6 A
peptide inhibitor of MUC-1C has been shown to downregulate
BCR-ABL and inhibit cell growth,16 indicating its value as a
therapeutic target.
We previously demonstrated4 decreased proliferation follow-
ing the transient expression of CCmut2, and these data are
represented here (Figure 5, vehicle treated). To determine the
eﬀects of selected pathways in combination with BCR-mediated
inhibition of ABL by the mutant coiled-coil, additional
experiments were carried out as before4 with drugs added 6 h
after transfection. Untreated groups were scaled to previous
data and compared to treated cells at 48 h. A signiﬁcant
reduction was seen across all samples when treated with the
CCmut2 (Figure 5, white bars), consistent with previous work,4
and further reductions were seen in the CQ and GO-201
treated groups when transfected with CCmut2 (CQ and GO-201
groups, white bars). In fact, GO-201 treatment reduces
proliferation independent of the transfected group but further
diminishes reduction in proliferation most in combination with
the mutant coiled-coil (GO-201 group, white bars).
CQ Enhances the Activity of Eﬀector Caspase 3/7 in
Concert with CCmut2. We next investigated whether increases
in apoptotic signaling could be enhanced using the transient
transfection of constructs with drug combinations at 48 h. Early
apoptotic events can be indicated by executioner caspase 3 or 7
cleavage products. These products were measured using a
luminescent DEVD substrate.36 The only combination which
resulted in a signiﬁcant (3 fold) increase in caspase 3/7 activity
was the CCmut2 with the CQ treated group (Figure 6; compare
GFP and CCmut2 bars in the CQ group). Other combinations
did not signiﬁcantly enhance caspase 3/7 activity.
Increased Apoptotic and Necrotic Activity Are
Observed Following CQ Combinations. In addition to
eﬀector caspase activity, later stage apoptosis and necrosis were
measured using cell permeable reagents demonstrating
apoptotic (phosphotidylserine externalization recognized by
Annexin-V) or necrotic (nuclear membrane permeability by
DNA intercalation of 7-AAD) events. At the earliest time
measured, CQ and GO-201 increased cell death response
(Figure 7A and D), though GO-201 aﬀected only the CCmut2
transfected population, and was not signiﬁcantly diﬀerent from
the vehicle treated group (Figure 7D). CQ has a broader
impact potentiating the CC transfected population speciﬁcally
(Figure 7A). Seventy-two hours after initial transfection, the
singular impact of the CCmut2 transfected cells becomes clear as
signiﬁcant increases are seen in the apoptotic population
(Figure 7B). The GO-201 apoptotic increase seen at 48 h
Figure 4. Autophagy occurs in K562 cells and is increased following
exposure to IM or the mutant coiled-coil (CCmut2). Shown is a
representative Western blot for LC3-I/II and at 24 h. Treatment with
imatinib or transfection CCmut2 in concert with CQ treatment
increases autophagic ﬂux, indicated by LC3-II expression compared
to that of LC3-I. This is given as the LC3-II/I ratio at 24 h indicated in
the table below the ﬁgure. n = 3.
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(Figure 7A) is reﬂected in the necrotic population at 72 h
(Figure 7E). CCmut2 alone signiﬁcantly increases apoptosis at
96 h (Figure 7C) and is signiﬁcantly enhanced by the addition
of CQ. While zil also increases apoptosis, it is not above vehicle
control levels. Necrosis at 96 h appears only to be impacted by
CCmut2 (Figure 7F).
■ DISCUSSION
In this study, we report that drug and transfection combinations
can enhance elimination of K562 CML cells. Using a novel
genetic therapy (CCmut2), we demonstrated enhanced apoptotic
cell death and reduced proliferation ability of CCmut2 expressing
K562 cells consistent with previous reports.4,12 We then
evaluated the transformative and proliferative capacity of cells
using a combination of constructs or drugs focused on
inhibiting BCR-ABL signaling and other leukemia-speciﬁc
pathways. Though we did not see a signiﬁcant reduction in
transformative ability with the transfection of a single plasmid
alone, the combination of constructs targeting Alox5 knock-
down with CCmut2 elucidated the importance of Alox5 in long-
term cell survival and colony forming ability (Figure 3).
Previous studies involving Alox5 in CML do not address the
transformative ability of K562 cells but focus more on stem-like
cells in in vivo models.5,15,24,31,37 Though other assays did not
indicate a robust role for Alox5 in apoptosis or proliferation, the
fact that Alox5 could be an important target in blast-phase
CML cells in addition to a primordial CML stem cell is an
interesting observation.
We also demonstrated further reduction in proliferative
capacity resulting from the combination of GO-201 or CQ and
CCmut2 transfections (Figure 5). Additionally, eﬀector caspase 3
and 7 activation increased following the combination with CQ
at 48 h (Figure 6). Finally, combining CQ and CCmut2 appear
to enhance apoptosis/necrosis when both exist in the cell long
enough to have an eﬀect individually (Figure 7). Interestingly,
increases in apoptosis and necrosis were primarily due to the
small molecule drug (CQ) or peptide therapeutic (GO-201)
(Figure 7A, D), then later aﬀected by the transfection (Figure
7B−C and E−F). This indicates a temporal shift in the activity
and eﬀect of the therapeutic, which may become important in
future studies. Together, these data suggest further increases are
achievable using a second agent in addition to the therapeutic
interfering peptide CCmut2. Speciﬁcally, combinations with
CCmut2 and CQ appear to have a broad eﬀect on proliferation
and apoptosis, followed by GO-201. In fact, the hydroxy-
chloroquine derivative of CQ is currently being investigated as
an adjuvant to IM therapy for CML in a clinical study
(NCT01227135). Future studies will evaluate the most potent
combinations in primary patient samples, including stem-like
CML cells. Importantly, this article demonstrates the eﬃcacy of
a combination based approach using small molecule or peptide-
based inhibitors to target both the causative oncogenic BCR-
ABL but also key alternative pathways in a blast-crisis CML cell
line.
Figure 5. K562 cell proliferation as indicated by trypan blue dye exclusion reveals that transfected cells subsequently treated with drugs can further
depress the proliferative capacity of K562 cells. CCmut2 has a signiﬁcant eﬀect alone, compared to that of the GFP control. Drug addition does not
signiﬁcantly aﬀect GFP-treated cells, with the exception of GO-201. CC + drug and CCmut2 + drug have further reductions in proliferation compared
to that of vehicle treated cells. GO-201 combined with CCmut2 has a potent reduction in proliferation compared to that of other drugs at 48 h. Two-
way ANOVA and the Bonferroni post-test have the following signiﬁcance levels: *p < 0.05, **p < 0.01; ***p < 0.001, n ≥ 3. ψ indicates at least p <
0.05 following a one-way ANOVA comparing the drug treated sample to the control (vehicle treated) in matched transfected groups, Bonferroni
post-test.
Figure 6. Apoptosis induction measured by activated caspase 3 or 7 is
increased in CQ treated cells when comparing GFP control and
CCmut2. Data is expressed as fold vehicle control. Two-way ANOVA
with Bonferroni post-tests. n = 5; *p < 0.05.
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Statistical details for 2-way ANOVA. This material is available
free of charge via the Internet at http://pubs.acs.org.
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Supporting Information 
 Statistical Details for two-way ANOVA. Figure 3.3: two-way ANOVA p-values: 
no significant overall interaction between short-hairpin transfection and coiled-coil 
transfection (p=0.3480). The transfection (GFP, CC, or CCmut2) significantly affects 
colony formation (p=0.0010). Knockdown transfection (shLuc, shAtg7, shMUC-1, 
shAlox5) also affects colony forming cells (p=0.0162). 
 Figure 3.5: two-way ANOVA p-values: no significant overall interaction 
(p=0.2042), with both transfection and drug treatment significantly affecting the result 
(p<0.0001). 
Figure 3.6: two-way ANOVA p-values: no significant overall interaction between 
drug treatment and transfection (p=0.3749). Transfection significantly affected caspase 
activity (p=0.0129) as did drug treatment (p=0.0087). 
 Figure 3.7: two-way ANOVA p-values: A) there is a significant overall 
interaction (p=0.0252), making the following p-values difficult to interpret. Transfection 
does significantly affect the result (p=0.0130). Drug treatment group significantly affects 
the result (p=0.0003). B) No significant overall interaction (p=0.2462). Transfection 
significantly affects the result (p=0.0146). Drug treatment group significantly affects the 
result (p=0.0006). C) No significant overall interaction (p=0.7156). Transfection 
significantly affects the result (p=0.0003). Drug treatment group significantly affects the 
result (p<0.0001). D) No significant overall interaction (p=0.3873). Transfection does not 
significantly affect the result (p=0.0590). Drug treatment group significantly affects the 
result (p=0.0098). E) No significant overall interaction (p=0.9854). Transfection 
significantly affects the result (p=0.0002). Drug treatment group does not significantly 
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affects the result (p=0.4144). F) No significant overall interaction (p=0.9397). 
Transfection significantly affects the result (p<0.0001). Drug treatment group 
significantly affects the result (p=0.0176). This information is available free of charge via 
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 Targeted therapy for chronic myeloid leukemia is centered on direct inhibition of 
the tyrosine kinase domain by small molecule therapeutics. This strategy has been 
successful in treating the majority of disease, but is subject to drug evasion following 
kinase domain mutations. Kinase activity results from transactivation of BCR-ABL1 
following an oligomerization event. The responsible and necessary domain for 
oligomerization is the CC domain in the N-terminus of BCR. Here we describe how a 
preferential and specific engineered mutant version of CC, the CCmut3, can be 
introduced as a therapeutic to limit oncogenic properties of the BCR-ABL1 containing 
cell. Analysis of apoptosis induction, proliferation, and transformative ability all 
demonstrate strong therapeutic potential in cell lines containing either wild-type p210 
BCR-ABL1, single kinase domain mutations (E255V and T315I), and in a compound 
(E255V/T315I) BCR-ABL1 kinase mutant cell line. Finally, we show efficacy of colony 
forming inhibition in patient samples from individuals with newly diagnosed chronic 
                                                          
1 Submitted to Leukemia 
myeloid leukemia and one harboring the T315I mutation. 
 
Introduction 
 The BCR-ABL1 reciprocal translocation t(9;22) (q34;q11) is the transforming 
event in converting hematopoietic cells into leukemia cells and the known cause of 
chronic myeloid leukemia (CML) (1, 2). Constitutive activity from the ABL1 tyrosine 
kinase in the fusion oncoprotein is a hallmark of CML and the specific target of small 
molecule therapeutics for the disease including the first inhibitor of its kind, imatinib (3-
5). Overall, tyrosine kinase inhibitors (TKIs) have displayed outstanding efficacy in 
CML, reducing disease burden, measured by complete hematologic (CHR) and 
cytogenetic response (CCyR), directly resulting in increased progression-free and overall 
survival rates compared to those before the introduction of TKIs (6-11). However, 
acquired kinase domain mutations confer BCR-ABL1-dependent resistance and have 
presented a significant barrier to TKI efficacy (12), leading to development of the next-
generation TKIs dasatinib, nilotininb and bosutinib and most recently the pan-BCR-ABL 
inhibitor ponatinib (13).  
 Ponatinib is notably the only effective agent for patients with the T315I mutation, 
a major breakthrough in disease treatment (14). Second generation TKIs produced a more 
reliable response to imatinib-resistant patients who carried any BCR-ABL1 mutation, 
producing CCyR rates of 47% and 32% for dasatinib and nilotinib, respectively (15). 
However, nilotinb failed to produce a CCyR in a majority of P-loop mutants including 
E255V. Additionally, although dasatinib treatment was able to produce a CCyR of 36% 
in patients with the E255V mutation, neither dasatinib nor nilotinib effectively inhibit the 
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T315I BCR-ABL1 gatekeeper mutation (15, 16). Interestingly, preliminary reports 
indicate patients can still acquire kinase mutations, including the E255V mutant, during 
ponatinib therapy, the long-term outcome of which is still unknown (17). Therapeutic 
efficacy becomes less clear with the development of multiple mutations within a single 
BCR-ABL1 gene, known as compound mutants in CML. The lineage of these are just 
now beginning to be understood (18). 
 While due focus has been given to ABL1-directed kinase inhibitors for CML, 
design of these small molecule inhibitors inevitably leads to increased propensity for 
selection of kinase domain mutations which inactivate drug binding (19). Few 
alternatives to inhibiting BCR-ABL1 activity and maintaining selectivity for the molecule 
have been proposed. One early proposal made by Ruthardt et al. described how inhibition 
of BCR-ABL1 oligomerization could block transactivation of ABL1 (20). By isolating 
and artificially introducing a mimic of the critical dimerization motif, helix α2 residing 
on the N-terminal coiled-coil (CC) domain in BCR, Ruthardt et al. demonstrated reduced 
phosphorylation of BCR-ABL1 and efficacy in other assays (21). However, the isolated 
wild-type helix 2 was inactive in the T315I mutant cell line (21, 22). 
 Recently we described two iterations of a mutant CC (called CCmut2 or CCmut3) 
with preferential specificity toward heterooligomerization with the CC of BCR (over 
homooligomerization with itself) (23, 24). This construct is similar to the Ruthardt helix 
2, but contains the full-length CC domain with engineered mutations for binding 
specificity within helix 2. Our previous results demonstrate significant inhibitory activity 
against wild-type p210 BCR-ABL1 containing K562 cells (23, 24), but BCR-ABL1 
mutant cell lines and patient-derived samples have not yet been examined. We 
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hypothesized that: 1) the efficacy of CCmut3 will not be affected by kinase domain 
mutation in BCR-ABL1, which inactivates current TKIs in vitro; and that 2) patient 
samples, regardless of kinase domain mutations, would also be susceptible to inhibition 
of BCR-ABL1 by CCmut3. To evaluate these hypotheses we studied the effect of CCmut3 
on Ba/F3 cells transduced with p210-BCR-ABL1 on induction of apoptosis, proliferation, 
and colony formation. We also performed the first analysis of CCmut3 efficacy in primary 
samples from newly diagnosed and TKI-resistant CML patients. 
 
 




 pmCherry-EV (empty vector) and pmCherry-CCmut3 have been described 
previously (24).The lentivirus control vector pCDH-EF-copGFP-EV was adapted from 
pCDH-CMV-MCS-EF1-copGFP (System Biosciences (SBI), Mountain View, CA). The 
CMV promoter and MCS were excised using the restrictions endonucleases SpeI and 
XbaI with compatible cohesive ends. The CMV fragment was removed using gel 
purification and the resulting DNA was ligated to form the final construct.  
 To make pCDH-EF-copGFP-CCmut3, sections of the construct were amplified 
separately by PCR and knit together using overlap extension PCR. First, EF1-copGFP 
was amplified from the SBI parent plasmid with a 5’SpeI and 3’BamHI site using the 
following primers: 5’-CAACTAGTAAGGATCTGCGATCGCTCC-3’ and 5’-CCAT 
CTGAGTCCGGAGCGAGATCCGGTGGAGC-3.’ CCmut3 was amplified from pEGFP-
CCmut3 described in (24) using the following primers containing a 5’BamHI site, a 
terminal TAG stop signal and a sequence complimentary to the polyA signal on the 3’ 
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overhang: 5’-CTCAGATGGATCCTTATGGTGGACCCGGTGGGCTTCG-3’ and 5’-
GTTATCTAGATCTACCGGTCATAGCTCTTCTTTTCC-3’. Finally, the polyA signal 
from pEGFP-C1 (Clontech Laboratories, Mountain Veiw, CA) was amplified to include a 
5’ complimentary sequence to CCmut3, and a 3’ SalI restriction site using these primers 
5’-GACCCGGTAGATCTAGATAACTGATCATAATC-3’ and 5’-GCTTACATGCGG 
CCGCGTCGACTGTGGGAGGTTTTTTAAAGC-3.’ PCR products were combined in 
two steps, first by combining the CCmut3-polyA and then by adding EF-copGFP by 
overlap extension PCR. The PCR product was digested with SpeI and SalI and ligated to 
the pCDH-CMV-MCS-EF1-copGFP vector (SBI) also cut with SpeI and SalI. 
psPAX2 was purchased from Cellecta, Inc. (Mountain View, CA) and pVSV-G was 
purchased from Clontech (Mountainview, CA). 
 
 
Cell Lines, Transfections, and Lentivirus Generation 
 
 Stable recombinant Ba/F3 cells transduced with wild-type p210 BCR-ABL1 (25), 
the kinase domain mutants p210-T315I, p210-E255V, or the compound mutant p210-
E255V-T315I were generated in the Deininger laboratory (26, 27). These cells were 
cultured in RPMI with 10% FBS, 1% penicillin, streptomycin, glutamine, and 0.1% 
gentamycin (RPMI complete). Additionally 0.1% MycoZap™ (Lonza Bio, Basel, 
Switzerland) was added to prevent possible mycoplasma contamination. The non-
transduced parental Ba/F3 cell line was grown in RPMI complete with 20% IL-3 
conditioned media generated using WEHI-3B cells (28), also grown in RPMI complete. 
Ba/F3 cells were transfected with plasmid DNA using the Amaxa nucleofection system 
(Lonza Bio). Four micrograms of plasmid DNA was added to 3 million cells in 100 µL of 
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solution V with supplement and nucleofected using program X-001. Cells were returned 
to plain RPMI for 20 minutes and then transferred to 3 mL of RPMI complete for 24 h. 
Cells were sorted on a BD FACSAria cytometer (BD Biosciences, San Jose, CA) for 
double-positive cells expressing mCherry and GFP then returned to RPMI complete for 
subsequent experiments. 
 293-FT cells (Life Technologies, Grand Island, NY) were grown in DMEM with 
10% FBS (Atlanta Biologicals, Atlanta, GA), 1% penicillin, streptomycin, glutamine, 
MEM-nonessential amino acids, and sodium pyruvate (Life Technologies). Cells were 
passaged every 2-3 days in T75 flasks, and grown to 65% confluence in T-175 flasks for 
transfection.  
For lentivirus generation, cells were transfected with 30 µg of the experimental 
construct pCDH-EF-copGFP-EV or pCDH-EF-copGFP-CCmut3, 5 µg of VSVG and 8 µg 
of psPAX2 using the Profection® mammalian transfection reagent (Promega, Madison, 
WI) according to manufacturer instructions. The DNA solution in 3 mL was then added 
drop-wise to T175 flasks containing 293-FT cells. After 48 h of transfection, viral 
particles were complexed with PEG overnight, pelleted, and resuspended in RPMI 
complete. Lentiviral titer was performed by seeding 50,000 293-FT cells per well in a 24-
well plate and adding serial dilutions of virus to the cells. Cells with GFP fluorescence 
were detected on a Guava easyCyte HT cytometer (EMD Millipore, Billerica, MA), and 








Patient Samples and Lentivirus Infection 
 
 Mononuclear cells (MNCs) from peripheral blood (PB) of patients with newly 
diagnosed CML or those with a documented T315I mutation were used in these studies. 
Prior to use in assays, cells were Ficoll-separated and used for automated isolation of the 
CD34+ fraction using an autoMACS Pro (Miltenyi Biotech). Fresh or frozen CD34+ 
progenitors from CML patients were kept at 1E6 cells/mL when possible in RPMI-
complete containing 20% FBS and 5 µL/mL StemSpan CC100 (Stem Cell Technologies, 
Vancouver, BC, Canada). Cells were infected with lentivirus at a MOI of 5 for each 
construct at 24 and 48 h following harvest (fresh) or thaw (frozen). Cells were subject to 
fluorescence-activated cell sorting on a BD FACSAria cytometer after 72 h, and GFP 
positive cells were returned to culture in RPMI complete with 5 µL/mL CC100 for future 
experiments. All patients gave their informed consent in accordance with the Declaration 
of Helsinki, and all studies with human specimens were approved by The University of 





 Cell proliferation was assessed using the CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (MTS) assay (Promega) according to manufacturer instructions. 
Briefly, 5,000 viable cells were added to a single well in 96-well plate in 100 µL RPMI 
complete medium. Three independent samples were seeded in duplicate for each time 
point. Cells were allowed to grow for 3 or 4 days and read at 490 nM on a SpectraMax 
M2 plate reader (Molecular Devices,Sunnyvale, CA) 3 h after incubation with the MTS 
reagent. 
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Apoptosis and Cell Death 
 
 Apoptosis and cell death were assessed via flow cytometry using a BD 
FACSCanto analyzer as described previously (29). Cell lines were pelleted and 
resuspended in AnnexinV-binding buffer (BD Biosciences) then analyzed following 
addition of the apopototic marker AnnexinV-APC (BD Biosciences or Life 
Technologies) and cell impermeable nuclear dye 7-AAD (BD Biosciences or Life 
Technologies). In addition to the APC or 7-AAD channel, events that were GFP and 
mCherry positive were also recorded. A minimum of 500 events were recorded. 
 
 
Methylcellulose Colony Formation 
 
 Following selection of transfected cells by cell sorting, cells were counted using 
trypan blue exclusion and seeded into a methylcellulose colony forming assay (CFA) as 
described previously (23). Briefly, mCherry-positive Ba/F3 cell lines were resuspended 
in IMDM with 2% FBS (Stem Cell Technology) at a concentration of 10,000 cells/mL. 
Three hundred microliters of this dilution was added to 3 mL of Methocult media 
(M3434 – Ba/F3 p210 wild-type and mutant lines or M3234 – Ba/F3 parental, Stem Cell 
Technologies). Approximately 1,100 cells, or 1.2 mL, were seeded per dish in duplicate 
for each transfection. Colonies were counted 7 days later in an area of 100 µm2 per dish. 
 Primary cells were seeded in Methocult H4230 (Stem Cell Technologies) as 
described previously (30). Briefly, lentivirus-infected (GFP+) sorted cells were counted 
by trypan blue exclusion and resuspended at a concentration of 5,000 cells/mL into RPMI 
complete. Four hundred forty microliters of this dilution was added to 1.8 mL of 
methocult with 11 µL of CC100 cytokines and with or without TKI as indicated in each 
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experiment. Approximately 1,000 cells, or 1.1 mL, were seeded per plate. Plates were 
incubated at 37C in 5% CO2 in a humidified incubator for 14 days. Hematopoietic 





 Lentivirus infected and sorted primary cells were counted by trypan blue 
exclusion and seeded at 10,000 cells per well in a 96-well plate following cell sorting. 
Cells were counted beginning on day 2, daily through day 7 to examine cell growth of 
each individual sample when sufficient number was available. TKIs imatinib (at 0 or 2.5 
µM for ND CML samples) or ponatinib (at 0, 10, 25, or 50 µM for T315I CML samples) 





CCmut3 Universally Potentiates Apoptosis of  
 
Ba/F3 Cells with p210 BCR-ABL1 
  
 Apoptosis was measured by flow cytometry at 72 h following transfection of 
either empty vector (EV) or CCmut3 constructs tagged with the mCherry fluorescent 
protein. Cell events which were AnnexinV positive and 7AAD negative are considered 
the purely apoptotic population (31, 32). This population is reported in Figure 4.1 for 
each cell line. Transfection of EV and CCmut3 did not differentially induce apoptosis in 
the parental Ba/F3 cell line lacking BCR-ABL1 expression (Figure 4.1a). Ba/F3 cells 
stably expressing wild-type p210 BCR-ABL1 show a significant induction of 
approximately 3-fold when transfected with CCmut3 compared to EV (Figure 4.1b). The 
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Figure 4.1. CCmut3 universally enhances apoptosis of Ba/F3 cells with p210 BCR-
ABL1. Flow cytometric analysis of transfected and sorted cells for apoptotic cell 
population at 72 h are displayed. Apoptotic and necrotic stains AnnexinV and 7AAD 
reveal (a) Ba/F3 parental cells are not affected by overexpression of the CCmut3 compared 
to EV control. (b) Ba/F3 p210 cells have a more than 30% increase in apoptotic 
population when treated with CCmut3 vs EV control. Single Ba/F3 p210 mutants (c) 
E255V and (d) T315I display a significant shift toward the apoptotic fraction when 
expressing CCmut3 compared to EV. (e) Finally, the Ba/F3 p210 compound mutant 
E255V/T315I line is also significantly more apoptotic when treated with CCmut3. n=3. 
Graphs display mean with error bars indicating S.E.M. Unpaired t-test significance levels 
are *p<0.05, **p<0.01. 
  
70
CCmut3 transfection is also effective in increasing apoptosis in single mutant BCR-ABL1 
cell lines (Figure 4.1c and 1d) similar to that of those with wild-type BCR-ABL (compare 
Figure 4.1b to c and d). When both ABL1 kinase domain mutations (E255V and T315I) 
are on the same molecule as a compound mutant (Ba/F3 p210-E255V/T315I), the CCmut3 
still demonstrates ability to induce apoptosis (Figure 4.1e). 
 
 
Proliferation of BCR-ABL1-Expressing Cells  
 
Is Inhibited by CCmut3 Expression 
 
 The MTS tetrazolium compound, which is bioreduced by cellular metabolic 
processes, was used to determine the proliferative capacity of Ba/F3 cells with or without 
BCR-ABL1 following EV or CCmut3 transfection (33). In BCR-ABL1-null cells, there 
was no difference in proliferation at either 72 or 96 h following transfection (Figure 
4.2a). However, Ba/F3 cells with p210 BCR-ABL did show sensitivity to expression of 
CCmut3 at 96 but not 72 h (Figure 4.2b). Single p210 BCR-ABL1 mutants demonstrated a 
small, yet significant inhibition of proliferation in the CCmut3 group compared with EV at 
72 h which continued to limit proliferation to a greater extent at 96 h when compared 
with EV expression in the same cell lines (Figure 4.2c and 2d). Ba/F3 compound mutant 
cells show a much diminished difference between EV and CCmut3 at 96 h when compared 
with other lines, including those with single mutations. A detectable difference is seen at 








 Figure 4.2. Proliferation of BCR-ABL1 expressing cells is inhibited by CCmut3 
expression. (a) Ba/F3 parental cells were not affected by overexpression of the CCmut3 
compared to EV control. (b) CCmut3 treatment of Ba/F3 p210 cells significantly reduced 
proliferation at 96 but not 72 h compared to EV control. (c) CCmut3 but not EV expression 
results in significant reduction of single Ba/F3 p210 mutants E255V and (d) T315I 
proliferative capacity at both 72 and 96 h time points. (e)The compound mutant line 
containing both E255V and T315I shows a smaller but significant shift at 96 h when 
comparing CCmut3 to EV, but no difference in proliferation at 72 h. n=3. Graphs display 
mean with error bars indicating S.E.M. two-way ANOVA was used to compare 




Colony Forming Cells (CFCs) Are Significantly  
 
Decreased Following Expression of CCmut3 
 
 A methylcellulose colony forming assay was used to define the transformation 
potential of cells transfected with either EV or CCmut3. As in previous assays, the Ba/F3 
parental cell line displayed no difference between expression of EV or CCmut3 (Figure 
4.3a). However, when the wild-type p210 BCR-ABL1 protein is present, CCmut3 almost 
completely eliminated CFCs when compared to the EV control (Figure 4.3b). Similarly, 
Ba/F3 E255V (Figure 4.3c) and Ba/F3 T315I (Figure 4.3d) also produced a greater than 
10-fold reduction in CFCs in the CCmut3 group compared to control treatment. Finally, 
expression of CCmut3 in the compound mutant cell line was able to reduce CFCs by about 
half compared to EV control (Figure 4.3e). 
 
 
Cells From Newly Diagnosed CML Patients Are Sensitive to CCmut3  
 
Lentiviral Therapy Ex Vivo 
 
 Mononuclear cells isolated from peripheral blood of newly diagnosed CML 
patients and enriched for CD34 (Table 4.1) were transduced with EV or CCmut3-
expressing lentivirus. Following sorting for infected cells, patient samples were seeded 
into a cell growth assay or colony forming assay. Viable cells determined by trypan blue 
exclusion over a 7-day period were split into three groups: EV, EV+IM and CCmut3. 
Viable cell numeration shows steady growth of the control (Figure 4.4a, circles). 
Addition of 2.5 µM IM to the EV-transduced cells on days 0 and 4 diminished growth 
uniformly on days 5-7 (Figure 4.4a, boxes). A comparable reduction in growth was also 
seen in the CCmut3 infected cells on days 5-7 (Figure 4.4a, triangles) and notably this 
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Figure 4.3. Colony forming cells are significantly decreased following expression of 
CCmut3. (a) Ba/F3 parental cells are not affected by overexpression of the CCmut3 
compared to EV control. (b) Transformative ability of Ba/F3 cells expressing p210 BCR-
ABL1 is greatly reduced CCmut3 treatment group. Likewise in the Ba/F3 p210 mutants (c) 
E255V and (d) T315I, more than 10-fold fewer colonies are present in the CCmut3 group. 
(e) Colonies per area are again reduced in the compound mutant cell line (Ba/F3 p210-
E255V/T315I) by CCmut3 compared to empty vector control, here by about 3-fold. n=3. 
Graphs display mean with error bars indicating S.E.M.; unpaired t-test significance levels 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































decrease appears to be persistent and more durable than transient IM addition. On day 7, 
CCmut3 treated cells were not only different from EV control, but also the IM treated 
group (Figure 4.4a, day 7 ѱ). 
 When infected cells were introduced into methylcellulose with growth factors, 
individual patient samples appeared to respond to both IM and CCmut3 similarly (Figure 
4.4b-e) with the exception of ND2 (Figure 4.4c), which had slightly more CFCs 
compared to EV+IM. All showed a marked reduction when compared with EV control. 
When data from ND1-4 were pooled and means compared, a significant (>50%) 
reduction from EV control was observed in both EV+IM and CCmut3 (Figure 4.4f). 
 
 
CCmut3 Can Effectively Inhibit T315I Mutant BCR-ABL1-Driven 
 
Transformation In Accelerated But  
 
Not Blast Crisis CML Ex Vivo 
 
 Samples R1 and R2 represent cells from the same individual at two time points 
approximately 6 months apart (Table 4.1). Following infection with EV or CCmut3, cells 
were seeded in a methylcellulose colony assay. For comparison, ponatinib at 10 µM 
(pon10) was added at time of seeding to both R1 and R2 samples. A clear reduction in 
CFCs can be seen in both EV+pon10 and CCmut3 when compared with empty vector 
infection in R1 (Figure 4.5a). Importantly, clinical documentation of a T315I mutation is 
reported for R1. However, when R2 is subjected to the same treatment, little to no change 
can be seen between treatment groups in CFC number (Figure 4.5b). Because no 
difference was seen in CFCs, a growth assay was performed similar to that depicted in 




Figure 4.5. CCmut3 is effective in T315I accelerated but not blast crisis stage disease 
for one case ex vivo. Colony forming assays were set up with two samples from the 
same patient approximately 6 months between peripheral blood collections. Each sample 
was thawed and transduced with either EV or CCmut3, following selection for transaction 
each sample was plated in triplicate (a) R1 displays sensitivity to transduction with 
CCmut3 or an intermediate dose of ponatinib (10 µM) compared to the EV transduced 
control. (b) R2 is a sample from the same individual in blast crisis who was reported to 
have failed ponatinib therapy at this time. CCmut3 here represents a ~25% reduction in 
colony forming cells. However, (c) growth analysis, also in a technical triplicate reveals 





infected with EV (Figure 4.5c, circles), and are not markedly growth-inhibited following 
escalating doses of ponatinib (Figure 4.5c, squares; upright triangles; inverted triangles). 
Additionally, CCmut3 does not limit the growth of R2 compared with EV or EV+pon 





 TKIs have a proven track record in CML with over a decade of use producing 
significant clinical benefit (34). However, current challenges in CML therapy include 
mutational escape, BCR-ABL1-independent disease, and drug tolerance to name a few 
(35-39). BCR-ABL1-dependent resistance is often the product of acquired mutations 
following therapy, but can also be derived from unpressured selection for a more highly 
active BCR-ABL1 kinase in ND CML (12, 40, 41). Because kinase domain-targeted 
small molecule inhibitors will inherently be subject to acquired resistance arising from 
mutations in this domain, we chose to examine the ability of a designed coiled-coil 
dimerization domain inhibitor to disrupt the key event necessary for autophosphorylation 
of ABL1, oligomerization (42). We previously reported that transfection of the CCmut3 in 
unmutated BCR-ABL1-expressing K562 cells successfully limited BCR-ABL1-driven 
oncogenic activity (24). The activity of the CCmut3 in BCR-ABL1 mutants was evaluated 
in this study. 
 First we verified that the CCmut3 did not cause significant toxicity in cells that are 
BCR-ABL1-null. We completed this objective by measuring the induction of apoptosis, 
proliferation, and generation of CFCs in a methylcellulose colony forming assay in the 
IL-3-dependent Ba/F3 parental cell line. In all experiments we see no difference between 
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transfection with an empty vector expressing mCherry and the same vector with CCmut3 
inserted on the C-terminus of mCherry as a fusion protein (Figure 4.1a, 2a, and 3a). 
These observations are in agreement with previous studies in BCR-ABL1-null lines 
COS-7 and 1471.1 (43), but these experiments represent an important control in a cell 
line with hematologic origin. Specifically, a low level of apoptotic cells is observed 
(mean of 5.97% for EV vs. 6.70% for CCmut3) with the majority of the cells falling in the 
live event gate (mean of 75.1% for EV vs. 66.6% for CCmut3, not significantly different 
by unpaired t-test). 
 Since previous studies demonstrated that CCmut3 was effective in limiting 
proliferation and transformation, as well as inducing caspase-dependent apoptosis in 
p210-BCR-ABL1 expressing human-origin K562 cells, we proceeded to validate efficacy 
of this construct in the murine pro-B cell line Ba/F3 with stably expressed p210 BCR-
ABL1 (with concurrent expression of GFP as an indicator of transduction), conferring IL-
3 independence (44). In our studies using this cell line, we found that CCmut3 was most 
effective in reducing the oncogenic transformation, as measured by CFCs, and almost 
completely eliminated CFCs in the same area compared with EV control (Figure 4.3b). 
Significant differences were also seen at 96 h in the proliferation assay (Figure 4.2b), and 
in apoptosis induction (Figure 4.1b). These results are in accordance with our previous 
report of the CCmut3 in p210 BCR-ABL1 leukemia cells (24). 
 Mutational status of BCR-ABL1 is an important factor in the choice of treatment 
for CML. Some patients with later stage disease became imatinib-resistant after initially 
responding to therapy. The cause of this resistance is typically due to a single mutation in 
the BCR-ABL1 kinase domain (45). Second generation inhibitors are able to treat some 
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but not all mutant BCR-ABL1, but the third-generation pan-BCR-ABL1 inhibitor, 
ponatinib, has demonstrated impressive potency against all known mutants (46). 
However, clinical recommendations still stress the importance of enrollment in trials for 
new therapies to circumvent problems such as drug intolerance, BCR-ABL1-independent 
resistance, and potential new acquired resistance to newer therapies (e.g., ponatinib) (39, 
47). With this in mind, we chose to examine the efficacy of CCmut3 in BCR-ABL1 mutant 
cell lines. We first chose the single mutant E255V for analysis because of varying 
documented activity against this mutant with current TKIs as discussed previously here 
and elsewhere (48). 
 The retrovirally-transduced, and p210 BCR-ABL1-containing, Ba/F3 cell line is 
conducive to high-throughput mutational analysis, and has been increasingly used as a 
model for drug screening (49). Efficacy of CCmut3 in cells harboring the E255V mutant 
was greater than or equal to that seen in the p210 wild-type strain. Apoptosis induction 
represented a more than 4-fold increase when treated with CCmut3 compared with EV 
(Figure 4.1c), while proliferation capacity was reduced by CCmut3 at both 72 and 96 h 
time points following transfection (Figure 4.2c). On the background of the E255V 
mutation, the CCmut3 appears to outperform the antileukemic activity seen in p210 cells, 
though direct statistical comparisons are not made here. Transformative ability is 
similarly inhibited by CCmut3 in wild-type and E255V experiments (Figure 4.3b and c). 
 While varying TKI inhibitory potency is observed against many single kinase 
mutants, the T315I gatekeeper mutation was universally out of reach until the 
development of ponatinib, designed with that mutation in mind (50). Though ponatinib is 
now approved for TKI-resistant patients and indicated specifically for individuals with 
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the T315I mutation, it was necessary to examine CCmut3 efficacy in the context of this 
single mutant. We found that the CCmut3 was able to induce a significant level of 
apoptosis compared to EV control in T315I cells (Figure 4.1e). Additionally, significant 
differences were observed in cell proliferation in cells with the T315I mutation at both 72 
and 96 h (Figure 4.2e) following CCmut3 transfection. Finally, CCmut3 significantly 
reduced CFCs compared to EV control (Figure 4.3e). Taken together, these data support 
the utility of CCmut3 efficacy against the T315I kinase domain mutant. 
 Third generation TKIs including DCC-2036 (currently in development) and 
ponatinib clearly show inhibition of kinase activity even in the presence of the T315I 
mutation (51). However, clinical efficacy following the genesis of compound mutants has 
not been evaluated. Recently, a study was completed by the Deininger group 
demonstrating the impaired utility of both ponatinib and DCC-2036 when used in the 
Ba/F3 BCR-ABL1E255V/T315I compound mutant cell line. The IC50 was increased from 2.3 
nM in nonmutant background to 425 nM, or 27 nM to 1272 nM in this compound mutant 
line for ponatinib and DCC-2036, respectively (52). Because of these observations, we 
chose to evaluate the efficacy of CCmut3 in the context of this compound mutant. 
 CCmut3 demonstrated efficacy, yet potency varied following treatment of 
compound mutant cells when compared to single mutants alone. Apoptotic induction in 
compound mutant cells was significantly more than the EV control (Figure 4.1e), yet not 
as significant as either mutant alone (compare Figure 4.1c and d). However, no 
significant difference in apoptosis was measured between single mutants and the 
compound mutant, all of which were treated with CCmut3 (one-way ANOVA, Tukey’s 
posttest). On the other hand, proliferation as measured by cell metabolism (Figure 4.2) 
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shows a very small, yet significant difference at 96 h between EV and CCmut3 treated 
compound mutant cells (Figure 4.2e). However, when compared with the values for wild-
type, single and compound mutants, CCmut3-treated compound mutant cells do not 
demonstrate a significant shift from the Ba/F3 parental control cells (one-way ANOVA, 
Tukey’s posttest, p<0.001). When we examine the transformation potential of the 
compound mutant line, treatment with CCmut3 confers a significant reduction in CFCs 
when compared with EV control (Figure 4.3e). However, when CCmut3 treatments are 
compared between cell lines the potency appears reduced compared with other lines 
(Figure 4.3e vs. 3b, c, and d). In fact, the compound mutant is different than all other 
BCR-ABL1 expressing lines measured (one-way ANOVA, Tukey’s posttest, p<0.05), but 
is also different from the Ba/F3 null line (p<0.001). 
 Reviewing the data in the Ba/F3 cell lines demonstrates the ability of CCmut3 to 
exert a notable inhibition in BCR-ABL1 driven activity. This is achieved with little 
toxicity to BCR-ABL1 null lines. Furthermore the ability of CCmut3 to maintain this 
activity in the presence of single and in some cases compound mutant versions of BCR-
ABL1 is an important step forward for a single-agent selective inhibitor of BCR-ABL1. 
 We went on to test the efficacy of CCmut3 delivered using a lentivirus in primary 
CML patient samples. In the samples selected, CCmut3 matched the performance of the 
most relevant TKI used for these conditions. Following lentiviral infection and selection 
of infected cells, primary cells from newly diagnosed CP-CML patients exhibited a 
sensitivity to CCmut3 and IM when compared to EV control in both a cell growth assay 
(Figure 4.4a) and methylcellulose colony forming assays performed on four ND CP-CML 
samples (Figures 4b-f). Significant inhibition was seen demonstrating efficacy in a 
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relevant clinical model. 
 Next, we sought to evaluate the activity of CCmut3 in a primary sample with a 
T315I mutation. Although not initially noted during sample selection, the two samples 
that were evaluated (R1 and R2) came from the same patient at two different time points. 
R1 was during accelerated disease phase with a documented T315I mutation. The current 
course of therapy for this individual at time of sample collection was 500 mg hydrea 
b.i.d., 0.5 mg anagrelide b.i.d., and intermittent peg-interferon. A second sample (R2) 
was collected when the patient presented in distress at a local hospital; they were taking 
ponatinib at the time of collection but had progressed to blast crisis phase. These samples 
were separately infected with lentiviral constructs for EV or CCmut3 and evaluated for 
colony formation in methylcellulose 14 days after cell sorting. Treatment with 10 nM 
ponatinib or with CCmut3 reduced the number of CFCs compared to EV control in R1 
(Figure 4.5a). However, a demonstrated reduction in colony number following treatment 
with any agent could not be seen in R2 (Figure 4.5b). To evaluate any potential 
susceptibility to ponatinib or CCmut3, a cell growth assay was started, and monitored for 5 
days. Again, no observable difference was seen in this assay between any constructs 
(Figure 4.5c). Following this result, we examined the status of p-Abl and p-CrkL in these 
samples and discovered no change in status of these phosphorylated proteins between 
untreated and ponatinib or CCmut3 treated samples, indicating the sample is not BCR-
ABL1-independent (data not shown). Though no specific cytogenetic data for the R2 
samples is available, we may speculate that secondary genetic or molecular abnormalities 
are contributing to the lack of efficacy in this CML blast crisis individual sample. 
Previously reported secondary abnormalities include p53 mutations (25-30%), p16/ARF 
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mutations (50%), or amplification of BCR-ABL1 (38%) (53). 
 In summary, novel therapeutics that selectively target BCR-ABL1 outside the 
kinase domain do not currently exist in the clinical domain. We have previously shown 
efficacy of such an inhibitor which is directed to disrupt the oligomerization event 
necessary for kinase activity of BCR-ABL1. This report demonstrates activity in another 
hematopoietic line with BCR-ABL1, in addition to minimal toxicity in BCR-ABL1 null 
status. Additionally, efficacy in single-mutant BCR-ABL1 cells is evident, where the 
majority of kinase inhibitors are not able to treat these single-mutants. Moreover, CCmut3 
appears to have some activity in against compound-mutants, where current state-of-the 
art inhibitors struggle. Finally, we show the effectiveness of CCmut3 in treating newly 
diagnosed CP-CML and accelerated phase-CML with T315I mutations ex vivo. 
However, when cells become BCR-ABL1-independent, CCmut3, or any single-agent 
BCR-ABL1 directed therapeutic fails to produce a response. 
 Going forward we plan to improve the delivery method of CCmut3, moving away 
from lentiviral delivery and toward a cell-penetrating peptide. Finally, stapled peptides 
will be explored to increase stability and potency. While all of these tasks are aimed at 
better BCR-ABL1 targeting, BCR-ABL1-independent targets could be incorporated by 
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 The discovery of the Philadelphia (Ph) chromosome in 1960 linked the BCR-
ABL1 reciprocal translocation to a Ph-positive myleoproliferative disorder (1-3). Chronic 
myeloid leukemia (CML) is universally caused by this chromosomal rearrangement, but 
the BCR-ABL1 reciprocal translocation can also be found in 25-30% of acute 
lymphoblastic leukemias (ALL) (4-6). For more than a decade, small molecule tyrosine 
kinase inhibitors have changed the course of Ph+ disease management, transforming a 
fatal disease into a manageable chronic condition, most notably in CML. This success 
was accomplished by inhibiting activity of the BCR-ABL1 constitutively active tyrosine 
kinase, the central event in disease initiation, first with imatinib, and later with 
subsequently improved TKIs. BCR-ABL1-selective inhibitors have focused entirely on 
the Y-kinase domain, with the exception of a series of investigations by Ruthart and 
colleagues, which proposed a competitive binder for the essential upstream BCR-ABL1 
dimerization/oligomerization event (7). Over the last 5 years, the Lim laboratory has 
focused on the N-terminal domain of BCR-ABL1, specifically the coiled-coil (CC), for 
potential therapeutic intervention in Ph+ disease. Our studies depart from the Ruthardt 
et al., work by not using a wild-type unmodified section of the CC, but instead are based 
on rationally designed mutations which facilitate preferential binding of the “CCmut” to 
BCR-ABL1 and limiting interactions with itself (also called homooligomerization). This 
increased heteroligomerization specificity utilized by CCmut peptides significantly shifts 
the preference for binding to (and inhibition of) the CC in BCR-ABL1 compared to 
homoligomerization between multiple BCR-ABL1 CC domains. 
 The studies presented here focus on the ability of our therapeutic to limit BCR-
ABL1 leukemogenesis in general; however, specific attention is given to the main 
barriers to the universal success of TKIs – resistance. A review of current therapy 
presented in Chapter 2 discussed the milestones of historical therapies and those under 
development, but also articluated necessary steps to cure CML. The third chapter 
explored using the CCmut2 as a baseline therapy and the possible avenues for adding 
secondary agents with the hope of addressing minimum residual disease, or BCR-ABL1-
independence. The most recent series of studies, presented in Chapter 4, investigated the 
potential to overcome mutational escape in the Y-kinase domain. Key points from these 
chapters will be reviewed and discussed here in reverse order. 
 
 
BCR-ABL1-Dependent Resistance: Solving TKI-Resistance Through  
 
Oligomeric Disruption of BCR-ABL 
 
 Oncogenic inhibition across varying mutational status of BCR-ABL1 can be 
achieved by introduction of the CCmut3. We observed that cells without BCR-ABL1 did 
not exhibit significant toxic effects following exposure to CCmut3, and that levels we did 
see were not different than those exposed to a control construct delivered using the same 
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mechanism. Accordingly, we showed p210-BCR-ABL1 is sensitive to CCmut3 
administration in the Ba/F3 cell line. This is in agreement with previous work by our 
group in K562 cells (8-10). 
 Kinase mutants are of increasing importance for CML disease management, with 
only one FDA approved agent available to treat all known single kinase domain mutants. 
We examined the efficacy of CCmut3 in two single Y-kinase domain mutants. E255V is a 
p-Loop mutation that confers resistance to imatinib, and a significant therapeutic barrier 
(requiring dose-escalation) for nilotinib and dasatinib. T315I is only treatable with the 
pan-BCR-ABL1 inhibitor ponatinib (FDA approved with an indication for patients who 
are TKI-resistant or have T315I), or the “switch-pocket” inhibitor DCC-2036 (which 
recently completed a Phase I/II trial) (11, 12). We observed a dramatic induction of 
apoptosis and reduction in proliferation and transformation following treatment with 
CCmut3 compared to EV control in both single BCR-ABL1 mutant cell lines. Finally, the 
compound mutant E255V/T315I was tested. This compound mutant was found to 
significantly impair the potency (measured by IC50) of both ponatinib and DCC-2036 
(13). CCmut3 demonstrated significant induction of apoptosis, as well as limiting colony 
forming ability with this compound mutant. Though we also noted a reduction in 
proliferation, this effect was less dramatic, yet still significant when compared with wild-
type or single mutants of BCR-ABL1 in Ba/F3 cells. 
 Though it is difficult to compare across cell lines, owing to possible differences in 
kinase activity (14) and growth potential of the cells prior to setting up assays, the data 
for CCmut3 across all Ba/F3 cell lines is presented side-by-side and normalized to the EV 
control (Figure 5.1). When viewed in this manner, single kinase mutants retain sensitivity 
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Figure 5.1 Summary of Ba/F3 CCmut3 experiments from Chapter 4. EV constructs are 
omitted from this data analysis for direct comparison of CCmut3 activity across varying 
cell line backgrounds. Initial comparisons were made only between EV and CCmut3 for 
each cell line. (a) MTS assays at 72 and (b) 96 h are shown across all cell lines for 
comparison. (c) Colony forming assay after one week in methylcellulose culture. (d) 
Apoptosis assay conducted after 72 h. n=3. One-way ANOVA with Tukey’s posttest, ns, 
not significant; *p<0.05, **0.01, ***p<0.001. 
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to CCmut3 while the compound-mutant stands out as being less sensitive, though still 
yielding a significant reduction (Figure 5.1c). CCmut3 apoptotic activity in p210-
containing cells is limited for this specific experiment, which becomes evident when 
comparing p210 to parental Ba/F3 controls (Figure 5.1d). 
 Fortunately, we were able to access patient samples for later experiments. These 
samples provided an advanced model for testing the efficacy of CCmut3, and an important 
step forward in efficacy validation. Newly diagnosed patients were sensitive to CCmut3 ex 
vivo as measured by cell growth and colony formation. Interestingly, a T315I mutant was 
also sensitive to CCmut3 in accelerated disease phase, but not in blast crisis phase. We are 
currently attempting to verify that this sample is BCR-ABL1-independent through 
analysis of phospho-ABL1 and the specific substrate for ABL1, phospho-CrkL. 
 While we did see activity in the T315I mutant of BCR-ABL1 with the CCmut3, 
Ruthardt and colleagues did not observe a potent reduction in transformation following 
treatment with the CC helix 2 construct. They did, however observe phospho-ABL 
reduction (15). This is a discrepancy that may be explained by either our incorporation of 
mutations or the inclusion of the helix 1 portion of CC. However, we have not yet 
completed a phospho-protein analysis of the ABL1 signaling network following 
treatment with CCmut3 in a mutant BCR-ABL1 background. 
 
 
BCR-ABL1-Independent Resistance: Necessity of a  
 
Second Leukemia-Specific Inhibitory Agent 
 
 Recent reports validate the survival of cells which harbor BCR-ABL1, but are not 
dependent on its signaling (16). This state of BCR-ABL-independence confers a 
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persistent cell population, likely leukemic stem cells (LSCs) which may be quiescent, 
leading to a small population of cells that will not die following TKI treatment (17). 
Presence of these cells leads to an overwhelming majority of patients who must remain 
on TKI therapy chronically, though a small percentage are able to stop TKI therapy and 
remain disease-free (18, 19). With this in mind, we decided to investigate the activity of 
CCmut3 combined with one of three secondary agents which targeted disparate pathways 
not directly involved with BCR-ABL1, but specific to the LSC vs. a normal HSC.  
 While we did not directly evaluate the hypothesis of BCR-ABL1-independence, 
we did investigate the ability of secondary agents with or without CCmut2 to potentiate 
cell death and reduce proliferation in a blast crisis phase immortalized BCR-ABL1 cell 
line (K562). For this series of experiments we chose assays that had previously shown 
efficacy with CCmut2. Depending on the assay, we saw differential specificity toward 
enhancement of antileukemic biology for the three agents. The most consistent response 
was to chloroquine (CQ), which at 10 µM was effective at blocking the autophagocytic 
process, leading to a combined effect of increased caspase 3/7 activity, drastically 
reduced proliferation and a somewhat nonspecific induction of apoptosis (as measured by 
AnnexinV and 7AAD). The nonspecific nature of apoptosis caused by CQ in this 
experiment may be the result of increased externalized phosphatidylserine mediated by 
the autophagic blockade and overproduction of membranous components inserted into 
the cell membrane. The mucin-1 peptide inhibitor developed by the Kufe group also 
showed promise, though further testing of a control protein revealed some significant 
toxicity (data not shown), which could be a product of the arginine-rich cell penetrating 
peptide on the N-terminus (20-23). The Alox5 pathway showed weak specificity toward 
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combinatorial reduction of colony formation. While interesting, several reports now show 
the role of arachadonic acid and Alox5 as differentiation controllers in leukemic stem 
cells (24, 25). Going forward, testing CCmut3 and Alox5 inhibitor combinations in LSCs 
may show increased differentiation markers such as CD11b/c and CD14 (20, 26). 
 Finally, the ability to study the true consequences of these combinations in a more 
robust model of BCR-ABL1-independence is warranted. Based on the data generated in 
primary patient samples (noted above), we would propose testing the BCR-ABL1 T315I 
blast crisis patient sample (R2) from Chapter 4 with a chloroquine combination 
(discussed in Chapter 3). Other interesting models would include a stromal-driven 
population of primary cells which would more closely model the BCR-ABL1-
independent LSC which is most likely in the bone marrow microenvironment (27, 28). 
 
 
Clinical Implications for Current and Future Therapies 
 
 Finally, it is necessary to update some information regarding available therapies, 
new developments concerning treatment strategies and other clinical concerns. Since the 
publication of Chapter 2 in 2011 (29), three new drugs have been approved by the FDA 
for CML therapy, the first of which, ponatinib, has already been mentioned elsewhere in 
this work. Accelerated approval for ponatinib was given in December 2012 under the 
trade name Iclusig™. Its specific indication is for: 
 the treatment of adult patients with chronic phase, accelerated phase, or blast 
 phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior 
 tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute 
 lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine 
 kinase inhibitor therapy. (30) 
 
Ponatinib does carry a black box warning for arterial thrombosis and hepatotoxicity, with 
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these adverse events occurring in 11% and three total patients, respectively (31). This 
potent pan-BCR-ABL1 inhibitor does effectively treat the T315I mutant as extensively 
described elsewhere in this thesis, and is the only approved drug indicated for these 
patients. 
 Bosutinib was granted approval in September of 2012 and was discussed in 
Chapter 2. Pfizer’s contribution to the CML landscape is classified as a second-
generation TKI, with similar indications as ponatinib.  However, it does lack the ability to 
treat the T315I mutant. 
 Finally, omacetaxine mepesuccinate (Synribo™) is a recently-approved 
therapeutic which is also indicated for chronic or accelerated phase CML patients who 
have resistance or intolerance to two or more TKIs. Approval for the injectable 
omacetaxine mepesuccinate, a protein translation inhibitor, was granted in October 2012. 
Interestingly, omacetaxine mepesuccinate, also known as homoharringtonine, was 
initially identified more than 40 years ago in leukemia-related studies (32). However, 
further development was put on hold following the success of TKIs. Mirroring its 
indications, it is clear that this drug was put back on the development track to address 
TKI-resistance or potential BCR-ABL1-independence (33). 
 As the therapeutic landscape becomes increasingly crowded, with five TKIs and 
one nontargeted agent approved in the last twelve years, the clinical management of CML 
becomes more of a puzzle. While we generally discuss the TKIs as “targeted” to the ABL 
kinase domain, the truth is they are simply targeted to kinases in general, with varying 
activity and specificity depending on the agent (see Table 2.1) (29). The secondary goal 
of clinical care will shift toward managing drug side-effects, with the first priority of 
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stabilizing the disease state. 
 There is also increasing prognostic evidence that a short time to CCyR or MMR is 
predictive of a durable response. This can be aided with early diagnosis and treatment 
with potent drugs (34, 35). Additionally, a renewed effort to maintain an international 
scale for PCR detection of BCR-ABL1 from RQ-PCR with the hope that certified labs 
will standardize the values for BCR-ABL1 copy number, leading to a uniform clinical 
interpretations of disease state (36). Finally, there has been continued effort to evaluate 
the dose scheduling or discontinuation of TKIs. Most recently, a discontinuation study 
evaluated patients who had undetectable minimal residual disease and found 47% did not 
relapse (37). Almost simultaneously, a report was published detailing a one-month-on, 
one-month-off study of elderly patients with CML. Patients on this study may have 
shown enhanced molecular disease markers, but maintained an acceptable level of overall 
and progression-free survival (38). This is important particularly because of potential 
comorbidities in elderly patients and the ability to reduce dosing requirements of the 
drug. 
 In conclusion, though many new drugs are available for CML, there is still a need 
for innovative new therapeutics that display curative potential. The ability to circumvent 
either BCR-ABL1-dependent (mutational escape) and/or -independent resistance will 
allow this critical breakthrough in CML therapy. Moreover, any drug which can reduce 












 Significant progress has been made since the inception of the CCmut concept. The 
initial focus on the CC of BCR was to develop a capture motif that could be combined 
with a ligand-inducible protein switch (39). By harnessing the protein switch developed 
by the Lim lab, able to drag the BCR-ABL1 to the nucleus (40-42), we aimed to restore 
the protein-tyrosine kinase 1 (c-Abl) apoptotic activity to the cell afflicted with the BCR-
ABL1 translocation and fusion products (43). To that end, the Lim laboratory attempted 
to modify the CC domain for better binding, resulting in the CCmut2 and later the CCmut3 
(8, 9). Additionally, exploration of mitochondrial targeting of BCR-ABL1 was explored, 
which produced impressive cytotoxic effects especially with the addition of imatinib, 
ultimately aiding in releasing BCR-ABL1 from its actin fillament tether (10, 44). 
 This body of work demonstrates the efficacy of CCmut2/3 as a combination therapy 
in concert with a secondary agent for enhanced cell toxicity, or alone against TKI-
resistant cell lines harboring kinase mutations. Most importantly, we show efficacy in an 
advanced CML model, as close to the clinic as possible – including samples from patients 
with CML, and in a patient with TKI-resistance in accelerated phase. However, we fail to 
demonstrate efficacy in a sample from a patient in blast crisis phase disease, who is also 
resistant to ponatinib. In blast crisis phase CML, significant disease remodeling can occur 
(45), possibly generating BCR-ABL1-independence. With this in mind there are several 









 As alluded to in Chapter 1, the function of p160 BCR in the greater context of 
normal cellular biology is not yet clear. To elucidate the potential unwanted interactions, 
a complete analysis of CCmut3/BCR partners is needed. However, even with this 
information, we must rely on the scientific community at large to contribute to the overall 
knowledgebase. For example, the fact that BCR and ABR have a RAC/GAP function, 
which is important in neuronal biology, may have little consequence unless that process 
also requires oligomerization of BCR (46). Moreover, the CCmut3 would have to gain 
access to the neuronal compartment through the blood-brain barrier to have an effect on 
this function. 
 Notwithstanding, we envision a binding assay that begins with an affinity tagged 
(e.g., 6xHIS, Flag, HA or Myc) CCmut3, which is then introduced into BCR-ABL1 null 
cells. Following expression and incubation, coimmunoprecipitation of the binding factors 
with CCmut3 would be carried out. This product could then be separated using SDS-
PAGE, stained for protein, and bands excised for analysis and identification via mass 
spectroscopy. This process could be performed for as many cell lines as was necessary 
and even translated to primary cells isolated from patients. 
 
 
BCR-Mediated Mutational Escape 
 
 A significant portion of this work was dedicated to discussing how CCmut3 is able 
to circumvent acquired kinase domain mutations in ABL1. However, the possibility that 
kinase-independent resistance to CCmut3 could arise is very real. Potential mechanisms are 
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somewhat limited, we contend, due to the inherent dimerization specification in the CC 
domain. To elaborate, we would argue that the purpose of the CC domain is to facilitate 
dimerization. CCmut3 has been designed to preferentially bind to the CC. It is possible that 
if a mutation occurred in this region, both CCmut3 and other wild-type CC (e.g., from 
BCR-ABL1 dimer partners) domains would fail to bind, resulting in an autoinactivation 
of oligomerization. This would ultimately have the same result as seen in deletion or 
binding disruption of the CC (47). 
 To test this hypothesis, we propose a mutagenesis screen to identify potential CC 
mutants that may confer resistance to CCmut3 and a simultaneous growth advantage. For 
this experiment, we would use Ba/F3 p210 cells and subject them to N-ethyl-N-
nitrosourea (ENU)-based mutagenesis (48). Following mutagen exposure, cells would be 
transduced with CCmut3 virus with a selectable (hygromycin or similar) eukaryotic marker 
to ensure expression. Cells that continued to grow above baseline would be removed, and 
lysed and their DNA amplified. The CC domain, along with the Y-kinase domain for 
completeness, could then be sequenced using multiple reads to determine a consensus of 
CCmut3-inactivating mutations. From this analysis we would hope to identify therapeutic 
barriers or susceptibility to CC-mediated mutational escape following administration of 
CCmut3. However, it is conceivable that mutant CCs already exist either in BCR or BCR-
ABL1 disease state. While we are not aware of any effort to analyze the sequence of CC 
patients to date, a comprehensive analysis of current domain mutations in primary 





Multiple-Domain Targeting of BCR-ABL1 
 
 Targeted therapeutics directed to inhibit the Y-kinase domain of BCR-ABL1 have 
been extremely successful (49). It may come as a surprise, however, that Ruthardt et al., 
reported that coadministration of the α-2 helix and imatinib (targeting of CC and Y-
kinase) results in enhanced sensitivity to the TKI (7). Recently Geoff Miller in the Lim 
lab explored a combination study treating cells with CCmut3 and with escalating 
concentrations of ponatinib. He discovered that ponatinib alone was able to significantly 
inhibit measured oncogenic processes, but coadministration of CCmut3 could elicit the 
same effect at a lower dose of ponatinib. A selection of that data is presented in Figure 
5.2 (unpublished data). Results were similar in other assays with a significant dose-
lowering capability at 1 nM ponatinib or 10 nM in T315I mutant cells.  
 This dose-lowering capability may become important in the management of 
adverse events by allowing patients to maintain a TKI which at higher concentrations 
would otherwise cause conditions indicated in the black box warning label. 
 
 
Size, Potency, Delivery, and Conjugation 
 
 The remainder of this future directions section surrounds the pharmaceutical 
engineering to enhance the stability and delivery of the CCmut3 to the target cell. Here we 
will focus on moving away from gene-based therapy and toward a more readily-available 






































































Figure 5.2 CCmut3 enables dose-lowering of ponatinib while maintaining apoptotic-
induction potency. mCherry control or CCmut3 were transfected into Ba/F3 p210 cells, 
and then treated with increasing doses of ponatinib as indicated. Apoptosis was measured 
by flow cytometry after 72 h of exposure to both treatments. 
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Peptide Size: The Elephant in the Room 
 
 The full CC domain is comprised of two α-helices represented by 72 amino acids 
(AA), which we have continued to use for the CCmut2 and CCmut3. This 72-AA mutated 
CC domain can efficiently disrupt dimerization of BCR-ABL1 homodimers to force a 
proapoptotic and antioncogenic phenotype (8, 9). The previous work on this domain 
suggested a truncation that has similar activity as our CCmut2/3 (15). However, we 
observed a discrepancy between our results and those previously reported regarding the 
ability to inhibit BCR-ABL1-driven transformation from a T315I mutant (14). It is 
unclear at this point whether there is added stability of the α1-helix or if it is the rational 
manipulation of the α2-helix that confers this activity. Geoff Miller is currently working 
on truncation mutants to resolve these questions. It should be noted that the potential for 
instability likely increases as the size of the protein is shortened. During the early 
experiments for Chapter 4, an isolated 72-AA peptide delivered using lentivirus failed to 
potently express CCmut3. It is unclear if RNA degradation occurred, or protein instability 
or increased degradation was the cause of this event (Figure 5.3). This problem was 
solved by fusing CCmut3 to EGFP for subsequent experiments. However, there are 




Hydrocarbon Staples: Good for the CCmut3-Inhibitory Environment 
 
 The CCmut3 is an ideal candidate for stapled-peptide technology. Peptide stapling 
can occur for many different motifs, but is uniquely suited for an α-helix (50). Peptide 
stapling provides stabilization for the desired motif through a hydrocarbon-conjugated 
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Figure 5.3 Stability of CCmut3 domain vs. CCmut3-EGFP fusion in viral producing 
and K562 cells. (a) Virally delivered empty vector (1), CC (2), or CCmut3 (3) in K562 
cells is not expressed at the corresponding size as should be detected by the BCR-N20 
antibody, BCR and P210 BCR-ABL are evident in lanes 1-3. A positive control, purified 
CCmut3 peptide collected from bacteria cells is in lane 4. Lane 5 shows K562 cells 
transfected with the CCmut3-EGFP fusion plasmid pEGFP-CCmut3 also show expected 
bands. (b) 293-FT virus-producing cells transfected with lentiviral plasmids expressing 
empty vector (1) or EGFP-CCmut3 (2). Virus harvested from cells run in lanes 1 and 2 was 
induced into K562 cells shown in lanes 3 and 4, with empty and EGFP-CCmut3 fusion, 
respectively. Lane 5 depicts the same 8 kDa purified CCmut3 as seen in Figure 5.3a, lane 
5. 
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linker attached to the peptide backbone Figure 5.4 (51). Currently, Aileron Therapeutics 
holds the technology patent for peptide stapling, but novel peptides requiring stapling can 
be out-licensed. The advantage in using a stapled peptide goes beyond specificity to 
include limiting degradation, and increasing cell solubility (52, 53). Geoff Miller has 
identified some putative residues which may be good candidates for staple conjugation. 
These residues are limited to the “back” of the α-helix, and would not occupy the same 
residues where designed mutations exist (e.g., G29, Q33, E36) (Figure 5.5). Because this 
technique requires more synthetic chemistry, it would be ideal to synthesize the CCmut3 
for this project. Overall yield and purity for synthetically produced proteins could be 
increased if the therapeutic α-helix were smaller, relating back to the previous series of 
proposed experiments regarding truncation. 
 
 
Penetrating the Target 
 
 Other work in the Lim laboratory by Ben Bruno centers on incorporating a 
leukemia-specific cell-penetrating peptide (LS-CPP) into the CCmut3. Work by Nishimura 
et al., described the specificity of a LS-CPP-containing the amino acid sequence 
CAYRLLR, which consists of a lymph node homing motif (CAY) and a cell-penetrating 
sequence (RLLR) (54). So far the LS-CPP-CCmut3 expression and purification from E. 
coli bacteria has been optimized, and we are beginning to test the uptake and dose-








 Figure 5.4 Differences in stability of stapled vs. nonstapled peptides. Here, a synthetic 
stapled peptide which mimics part of the p53-binding domain is compared to an identical 
nonstapled, wild-type peptide. This was a snapshot from a replica exchange molecular 
dynamics simulation using Schrodinger Suite 2009 and Pymol. 
 
This frame from the YouTube video located at the following link was obtained with 









Figure 5.5 CCmut3 stapling locations. (Top) A ribbon diagram representing the entire 
CC, α-1 and α-2 helixes, is illustrated. The CCmut3 (with highlighted green side chains) is 
interacting with wild-type CC (red side chains). Orange highlighted amino acids 
represent potential peptide hydrocarbon stapling locations. (Bottom) The above diagram 
is turned on its side, with the α-1 helix removed for clarity. The wild-type CC is now in 





Dimerization Motifs in Oncogenic Fusion Proteins 
 
 The BCR-ABL1 fusion protein and resulting therapeutic development of TKIs for 
disease management are a prototype for rational drug design. As we continue to show 
efficacy of the CCmut3 in this disease, we must also consider other disease-causing 
translocations which incorporate dimerization domains. A tangible example is non-BCR-
ABL1 (Ph-like) ALL, which in some cases harbors a BCR-JAK2 protein fusion product 
responsible for enhanced kinase activity. This aberrant kinase activity cannot be 
ameliorated with either a JAK2 inhibitor (XL019) or dasatinib (55). When considering 
non-BCR fusions, these new dimerization domains may also be susceptible to rational 
design of a dimerization inhibitor as we did with the CCmut3. While not all fusion 
products exhibit kinase activity, DNA interactions can equally drive oncogenesis after 
fusion by initiating transcription following dimerization (56). Examples of other 
dimerization domain-containing oncogenic fusion proteins include: the TFG-ALK (CC 
domain – kinase) fusion in lymphoma and non-small cell lung carcinoma (57); MLL-
ENL (AT-hook domain – trans-activator helix) fusion in ALL (58); and EWS-ATF1 
(EAD domain – leucine-zipper) in solid tumors and melanomas (59). Disruption of 
kinase activity, or DNA transcription could be specifically inhibited using dimerization 
disruption (similar to CCmut3) rather than a kinase inhibitor, or by the myriad of anti-





 There is significant progress being made in the study of the CCmut3 as a cancer 
therapeutic with utility in Ph+ leukemias. If any or all of the above proposed 
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improvements to CCmut3 delivery prove to be successful, there is ultimately no reason not 
to combine them into a single therapeutic agent with the highest possible potency and 
specificity for BCR-ABL1 dimer inhibition. As work continues on this project, we hope 
to one day see this agent available clinically. To this end we have filed several invention 
disclosure forms with the University of Utah Technology Commercialization Office 
(TCO); however, at this time no patents have been filed by the University on our behalf. 
As stepwise improvements are made, we will continue to file for protection of intellectual 
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